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“All substances are poisons: there is none which is not a poison.  The right dose 
differentiates a poison from a remedy.” 
    Paracelsus (1493–1541) 
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A CLINICAL DECISION SUPPORT SYSTEM FOR THE TREATMENT 
 
OF COMMON TOXIN OVERDOSE 
 
JON BRANTLEY LONG 
 
ABSTRACT 
Poisonings account for 0.8% of emergency room visits each year.  Our review of current 
toxicological resources revealed a gap in their ability to provide expedient calculations 
and recommendations, as they are broad in scope and time-consuming to read. Time is 
crucial in a toxicologic emergency.  Delay in first dose can lead to life-threatening 
sequelae.   
To bridge the gap, we developed the Antidote Application (AA), a computational system 
that automatically provides patient-specific antidote treatment recommendation(s) and 
individualized dose calculation(s).  We implemented 27 algorithms that describe FDA 
approved use and evidence-based practices found in primary literature for the treatment 
of common toxin exposure. The AA covers 29 antidotes recommended by Poison Control 
and toxicology experts, 31 toxins from 19 toxin classes, and over 200 toxic entities. We 
implemented the AA in two formats: a standalone downloadable application for offline 
use and an online web application.  The AA represents a unique educational resource for 
the study of toxicology with the potential of being adopted for point of care decision 
support.  The system also provides guidance for reporting toxic exposures regionally and 
nationally as required by accrediting bodies and some states.  The AA system has the 
potential for reducing initial dose delays and medication errors.  To the best of our 
knowledge, the AA is the first educational and decision support system in toxicology that 
  viii 
provides patient-specific treatment recommendations and drug dose calculations. The 
downloadable and online Antidote Applications are publically available at 
http://www.met-hilab.org/files/antidote/antidote_application.jar and http://projects.met-
hilab.org/antidote/ respectively.  
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PREFACE 
Death comes in July.  I’d heard clinicians in the hospital setting mutter this under their 
breath a few times.  It wasn’t until my third or fourth year working as the only pharmacist 
on duty overnight at a busy urban teaching hospital in New York that I finally understood 
what that meant.  You see, at U.S. teaching hospitals, July is the month when medical 
students become interns, interns become residents, and residents become fellows, and 
fellows begin their career.  Interns are usually left to cover the overnight shift while 
residents, fellows and attending physicians are either sleeping or altogether absent for a 
long awaited summer vacation.  It’s July!  It is a well-known and documented fact that 
there is an increase as high as 10% in mortality rates in teaching hospitals largely due to 
medication prescribing errors during July. 
In July of 2011, while answering one request after another about drug dosing 
information, I asked some of the young interns why they didn’t use Clinical 
Pharmacology or Facts & Comparisons.  Most of them stated that it was too much 
information.  It occurred to me that the current status of electronic drug information, 
though comprehensive, lacked the ability to present patient-specific drug dosing and 
treatment recommendations.  That is when I started my search for a better way of 
presenting drug information.  By September of 2012, I had successfully matriculated into 
the BU CIS Health Informatics program hoping to gain the skills necessary for creating a 
solution to this problem.  I was lucky enough to find Drs. Zhang & Brusic who gave me a 
chance to create one.   
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1.  OVERVIEW 
 
In this chapter we will describe currently available drug information, medical literature, 
and clinical decision support in toxicology, discuss their strengths, shortcomings, and 
impact in the hospital setting, and present how drug information is accessed in emergency 
situations.  In particular we will focus on how clinicians obtain drug information during 
toxicologic emergencies.  We will also discuss the current clinician protocol for 
contacting Poison Control for advisement on therapy for poisoned patients.  The thesis 
statement is presented and a summary of the thesis contribution follows. 
 
1.1 Background 
In medicine, drug information is presented in many forms such as FDA approved 
package inserts, primary literature, tertiary literature, clinical decision support systems, 
and electronic drug information databases.  In emergency situations like poisoning, 
salient communication of drug use (or indication), dosing, and other essential information 
is important in the rapid delivery of lifesaving medical interventions.  
Package inserts or drug monographs contain all FDA approved uses (indications) and 
drug labeling information.  They also contain a great deal of information the clinician 
may find useful for study. Indications and usage, dosage and administration, 
contraindications, mechanism of action, pharmacology, pharmacokinetics, product 
formulation, dosage forms and strengths, and adverse reactions are some of the topics 
commonly covered in the package inserts.  Though informative, they are not searchable 
  
2 
and therefore not helpful in an emergency situation.  They are, however, the primary 
source for FDA approved drug dosing and drug use information. 
At times some unapproved or “off-label” uses of a drug is described in primary literature 
in the form of single case studies or a collection of them.  This is useful as medical ethics 
and law prevent certain pharmacological studies in special populations such as infants 
and children.  For example, it would be considered cruel to intentionally poison humans 
to test the efficacy drug/antidote as a cure.  Yet, it is considered the duty of a clinician to 
report the findings of the use of an antidote in a patient that was accidentally poisoned.  
Though very useful, primary literature is even more difficult to search for drug use and 
drug dosing information.  Furthermore, the information may not be the most recent or 
reliable. 
Tertiary literature sources are very useful in the study of various medical disciplines.  
They contain background information on disease states and the pathophysiology behind 
them.  They also discuss the treatment of disease.  In toxicology some of the most useful 
sources are collections of literature by numerous authors, who are experts in the field and 
have made considerable contributions to research and primary literature in toxicology.  
The expert knowledge they impart is vast.  Though very helpful for study, again, in an 
acute situation, tertiary sources are not readily searchable for drug use and drug dosing.  
Tertiary sources are often retrospective and take a longer period of time to produce, 
which often results in outdated information. 
Clinical decision support comes in many forms in medicine.  Print is one of the oldest 
medical decision support forms that still persist.  However, in acute care situations, it 
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provides limited support for rapid clinical decision-making.  Electronic forms have 
largely eclipsed printed text for point of care clinical decision support. In the U.S., there 
is the toll free Poison Control Center Hotline for assisting clinicians in decision-making 
during toxicological emergencies [1].  This service is very useful in clinical decision 
support for toxic exposure, yet is limited by its mode of communication - verbal 
interaction via telephone.  One major issue with verbal order instruction from Poison 
Control is the lack of countersignature measures for order verification.  Further, this 
resource is unavailable during interruption of telecommunication services. 
Electronic clinical decision support systems (CDSS) are computer systems designed to 
impact clinician decision-making about individual patients at the point in time that these 
decisions are made [2]. It is one of the most promising tools to mitigate the ever-
increasing complexity of the day-to-day care practice of medicine. CDSSs enable fast and 
easy queries in an acute situation and provide pertinent information at the point of care.  
This represents a significant advancement over searching the various forms of print 
medical literature for information. Although the majority of CDSSs are integrated as 
modules of comprehensive electronic health record (EHR) systems, stand-alone CDSSs 
have also been developed [2].  CDSSs are also manifested in EHR systems in the form of 
alerts triggered by threshold lab values, drug interactions, drug duplication and the like 
described in the clinical decision support rules of the Health Information Technology for 
Economic and Clinical Health (HITECH) Act [3]. 
One unique area of medicine that has an attached sense of urgency is toxicology - 
specifically, acute toxic exposure or overdose in humans.  There are a number of CDSSs 
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or drug information databases that either focus exclusively on toxicology or cover 
toxicology in addition to all subspecialties of drug information. We observed several 
common limitations in these systems and they are comparatively difficult to navigate in 
an acute situation.  
In many CDSSs that address medication dosing and treatment, information often is 
presented in a format that mimics drug monograph material and goes on for multiple 
pages.  Most drug monograph information related to a drug product is included, such as 
contraindications, drug-drug and drug-food interactions, mechanism of action, 
mechanisms of toxicity, indications, product formulations, side effects, etc.  The major 
difference between drug monographs and CDSSs is the addition of unapproved uses with 
supporting primary literature references.  In most emergency circumstances drug dose 
recommendations associated with a single specific use (indication) are all that is needed. 
Current CDSSs present all FDA (U.S. Food and Drug Administration) approved and 
unapproved clinically accepted uses (indications) of the antidote to the user at once.  This 
often takes up multiple pages covering all scenarios for each specific indication, e.g., 
acetaminophen poisoning, expectoration, mucolysis, renal failure prophylaxis, etc.  
Consequently, the description of the antidote’s use in overexposure to a particular toxin is 
buried frequently among other irrelevant indications.  Also, the information about the use 
of an antidote for toxic exposure usually covers all patient demographics (age, weight, 
clinical status, sensitivities, etc.), routes of administration (intravenous, intramuscular, 
oral, rectal, etc.) and exposure scenarios (chronic or acute).  For example Clinical 
Pharmacology, a subscription-based online drug information database with clinical 
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decision support tools [4],  displays the extensive treatment and dosing recommendations 
for acetaminophen overdose [5].  
The full set of recommendations of acetylcysteine in the treatment of acetaminophen 
overdose, one of acetylcysteine’s many FDA approved uses, takes up two web pages.  
The dosing recommendations continue on for several more pages containing irrelevant 
indications such as bronchopulmonary disorders, nephrotoxicity prophylaxis, etc.  The 
information provided by Clinical Pharmacology is considered among the most concise, 
well-referenced of therapeutic recommendations in medicine [4].  Databases and CDSSs 
such as Clinical Pharmacology are valuable resources for research and educational 
purposes.  However, the collection of recommendations is too voluminous and 
overwhelming to support timely clinical decision making in an acute situation like 
acetaminophen overdose.  A CDSS that provides accurate, concise, and individualized 
recommendations based on each patient’s specific parameters is desirable. 
Another problem noted during our review is that most CDSSs are only available online.  
For a major metropolitan area, this is likely not an issue.  However for rural clinical 
settings where connectivity can be sporadic, an online CDSS can be suspended without 
notice.  Having an offline CDSS is essential in situations where power supply or 
communication services cannot be guaranteed. 
Further, general-purpose CDSSs cover a wide range of medical specialties.  
Consequently, they often provide information not pertinent to a poisoning emergency. As 
shown in the above-mentioned acetaminophen overdose example, users have to navigate 
voluminous electronic recommendation pages with unnecessary distractions.  Even in 
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toxicology specific CDSSs, the therapeutic information are presented in an all-inclusive 
manner, not specific to any individual patient population.  To further complicate matters, 
toxicology specific CDSS are usually an adjunct module to a larger clinical CDSS such 
as Clinical Pharmacology’s ToxEd [6].  This often makes it difficult to locate those 
modules.   
The majority of the available CDSSs do not provide reporting guideline 
recommendations.  In fact the only reference sources found in this project that state 
clearly that the regional Poison Control center should be contacted are the printed 
antidote/toxin quick reference charts and Medline Plus[7-9].  This is a significant 
omission, as some states in the U.S. have laws requiring the mandatory reporting of 
poisonings [10].  The print antidote and toxin charts have no recommendations for 
reporting an overdose to the Federal Adverse Event Reporting (FAER) system [8, 9]. 
Further, though some of the CDSS reviewed in this thesis offer drug dose calculators, 
none of them are patient and indication specific.  
As many hospitals in the U.S. are teaching hospitals, a large portion of their physician 
staff has a low level of experience and a higher potential for error.  Medication error rates 
among new physician staff are much higher especially during initial hospital training 
[11].  The current status of drug information and CDSS is quite confusing and difficult to 
navigate.  Clinicians need a simple-to-use tool with patient specific treatment 
recommendations to assist them in making rapid decisions about appropriate drug 
therapy.  This tool needs to be easily navigable and provide only relevant drug indication 
and individualized dosing information.  This is of particular importance in the practice of 
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emergency medicine and toxicology.  We found there is a clear need for a toxicology 
specific CDSS that makes patient specific treatment recommendations, performs 
individualized dose calculations, provides appropriate poison and adverse event reporting 
suggestions, and overcomes limitations of current drug databases and CDSSs.   
1.2 Thesis Statement  
In this project, we aim to design and implement a computational system that 
automatically recommends individualized antidote treatment regimen(s) and patient-
specific doses based on each patient’s parameters. The aim is to support education for 
treatment of common toxin overdose by implementing a computational system that 
makes patient specific treatment recommendations including individualized dosing 
calculation, provides a reporting solution linked to Poison Control and the Federal 
Adverse Event Reporting System, and is well referenced.  When fully tested and 
validated, the system can be used as a point of care tool that supports clinical decision-
making, reduction of medication errors, and reduction of medication delays. The 
antidotes and toxins covered by this project shall include those recommended for 
common use in hospitals by Dart et al. as listed in Table 1.1 [12].  
The developed CDSS has the following characteristics: 
1) Available offline and online 
2) Provides patient specific dose calculations for all age groups ranging from 
newborns to elderly adults 
3) Provides patient specific treatment recommendations  
4) Is exclusively for Toxicology (poisoning and overdose) 
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5) Is linked to Poison Control and FAER 
6) And is well referenced  
 
To the best of our knowledge, as of now, there is no clinical decision support system that 
meets all of the above-mentioned criteria.  
 
Table 1.1 Antidotes commonly stocked by hospitals and the toxins for which they are used 
(adapted from Dart et al. [12]). 
Antidote Toxin 
Acetylcysteine Acetaminophen 
Crotalidae Polyvalent Immune‡ 
Fab, ovine 
North American crotaline snake envenomation 
 
Antivenin (Latrodectus mactans) Black widow spider envenomation 
Antivenin (Micrurus fulvius) 
Eastern and Texas coral snake 
Envenomation 
Atropine sulfate 
Organophosphorus and N-methyl 
carbamate insecticides 
Botulism antitoxin, equine (A, B) 
Botulism 
 
Botulism immune globulin (BabyBIG) Infant botulism 
Calcium chloride 
Calcium gluconate 
Fluoride, calcium channel blocking agent 
Calcium disodium EDTA 
Lead 
 
Calcium trisodium pentetate 
(Calcium DTPA) 
Internal contamination with  
plutonium, americium, or curium 
Cyanide Antidote Kit OR Cyanide poisoning 
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Hydroxocobalamin hydrochloride  
Deferoxamine mesylate Acute iron poisoning 
Digoxin Immune Fab Cardiac glycosides/steroid toxicity 
Dimercaprol Heavy metal toxicity (arsenic, mercury, lead) 
Ethanol Methanol, or ethylene glycol poisoning 
Fomepizole Methanol, or ethylene glycol poisoning 
Flumazenil Benzodiazepine toxicity 
Glucagon hydrochloride Beta-Blocker, calcium channel blocker 
Methylene blue Methemoglobinemia 
Naloxone hydrochloride Opioid and opiate drugs 
Octreotide acetate Sulfonylurea-induced hypoglycemia 
Physostigmine salicylate Anticholinergic syndrome 
Potassium iodide Thyroid radioiodine protection 
Pralidoxime chloride 
Organophosphorus insecticide 
Poisoning 
Pyridoxine hydrochloride Isoniazid, hydrazine and derivatives 
Prussian blue Thallium/radio-cesium 
Sodium bicarbonate 
Sodium channel blocking drugs, 
urine or serum alkalization 
 
1.3 Contribution of the Thesis 
The original contributions of this research work include the development of the Antidote 
Application (AA) a computational system that automatically recommends individualized 
antidote treatment regimen and patient-specific doses for all age groups ranging from 
newborns to elderly adults. The AA was implemented in two formats: a standalone 
downloadable application for offline use (hereinafter referred to as Java AA) and an 
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online web application (hereinafter referred to as Web AA).  The AA hosts 27 algorithms 
for the treatment of common toxin exposure in North America. It covers the 29 antidotes 
recommended by Dart et al. [12], 31 specific toxins and 19 toxin classes.  These specific 
toxins and toxin classes represent over two hundred toxic entities covered by this system.  
Phone numbers and links to regional PCCs and the federal adverse event reporting 
mechanism (FAER) are included in the AA.  The AA represents a unique educational 
resource for treatment of common toxin overdose.  After rigorous review by 
toxicologists, the AA can also be used as a point of care clinical decision support system.  
 
1.4 Organization of the Thesis  
In this thesis, we discuss the history of toxicology, literature concerning toxicology and 
medical algorithms, and review electronic clinical decision support systems in Chapter 2. 
In Chapter 3 we describe the materials and methods used to develop the medical 
algorithms used in the AA and discuss several complicated examples of algorithm 
development.  The remaining algorithms are described in Appendix A.  In Chapter 4 we 
demonstrate the results produced by the AA in the case of the several algorithms 
described in Chapter 3. Chapter 5 summarizes the contributions of the AA, describes its 
future direction, and discusses several related issues that were revealed in the course of 
the project.  
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2 LITERATURE REVIEW 
2.1 Toxicology 
2.1.1 Definition of toxicology 
The word toxicology comes from root toxico- meaning poison and the suffix -logy 
meaning, “to speak thusly” or, more commonly, “the study of.”  The Society of 
Toxicology defines toxicology as, “the study of the adverse effects of chemical, physical 
or biological agents on living organisms and the ecosystem, including the prevention and 
amelioration of such adverse effect [13].”  Toxicology is considered one of the oldest 
sciences known to mankind.  Determining whether a plant or creature is poisonous has 
long been a priority throughout human existence.   
In toxicology, adverse effects are harmful effects that occur as a result of the exposure to 
a toxin or toxicant.  A toxin usually refers to a poisonous substance that occurs naturally.  
Toxins may be plant derived (phytotoxin), animal derived (zootoxin), bacterium derived 
(bacteriotoxin), or naturally occurring heavy metals.  Toxicant is a term used when 
speaking of any poisonous chemical or byproduct produced by manmade activities such 
as heavy metal byproducts, solvents, vapors, pesticides, radiation, and radioactive 
materials.  Toxicity is the degree to which a substance can be harmful to an individual or 
organism. 
Toxicity develops through the exposure of a toxic (poisonous) substance.  Several factors 
affect how toxicity develops in humans – dose, route of exposure, duration of exposure 
and frequency of exposure.  The Swiss physician Paracelsus (seen in Figure 2.1) stated 
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that, “All substances are poisons: there is none which is not a poison.  The right dose 
differentiates a poison from a remedy.”  For example, the LD50 (Lethal Dose 50%) of 
table sugar (sucrose) in rats is 29700 mg/kg [14].  Though this may be true, the likelihood 
of an overdose of table sugar is very low. 
   
Figure 2.1 Paracelsus "Father of Toxicology." 
The LD50 of ricin via injection into mice is 0.005mg/kg.  However, the injection of ricin 
is also very rare.  The antidote application focuses on the most common toxins and 
toxicants in North America known to cause serious illness or death.  As the dose of a 
substance increases, the likelihood of an observable effect increases.  The point at which 
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an observable effect becomes apparent is called the threshold.  In toxicology this 
threshold level is also known as the “NOEL” or no observable effect level below which 
no negative or toxic effect is observed.  Figure 2-1 gives an example of how this may be 
observed on a graph. There are several primary routes of exposure, which include the 
skin (dermal exposure), the digestive tract (ingestion), and the lungs (inhalation).  Other 
common routes of exposure include the eye and via injection.  
 
Figure 2.2 Threshold effects for dose. 
Common injection routes include intradermal (injection between layers of the skin), 
subcutaneous (injection under skin), intramuscular (injection within muscle), intravenous 
(direct injection into a vein), and intraperitoneal (injection into the peritoneum).   
Duration and frequency of exposure contribute to the dose of a substance.  Duration can 
be classified as acute or chronic.  Acute exposure usually lasts 24 hours or less and 
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involves a single exposure.  Chronic exposure usually refers to the repeated exposure to a 
substance over a period of time.   
2.1.2 Clinical Toxicology 
There are nine disciplines in toxicology - environmental, occupational, regulatory, food-
born, clinical, descriptive, forensic, analytical, and mechanistic toxicology. In this work, 
we focus on the discipline of clinical toxicology.  Clinical toxicology is the study of the 
adverse effects of acute and chronic exposure to toxic substances [15]. 
In 2012 Poison Control Centers (PCCs) in the U.S. recorded 2,275,141 human exposures 
to toxic substances. Of these 613,412 were managed in a healthcare facility (HCF) [16].  
Poisonings account for 0.8% of emergency department (ED) visits each year [17], 
representing a significant health care concern. As of 2014, The American College of 
Medical Toxicology lists only 177 licensed physicians in the Directory of Inpatient 
Medical Toxicology Services in the U.S. and most of them are clustered in major 
metropolitan areas [18].  This may result in a disparity in the quality of care received by 
poisoned patients across the country.   
As a poisoned patient presents in the ED, the physician must rapidly assess the situation 
by performing a differential diagnosis. Typically this includes recording the patient 
history either from a witness or the patient himself, recording circumstances surrounding 
the event such as suicidal letters or receptacles of toxic substances surrounding the 
patient, performing a physical examination, taking vital signs, and utilizing other tools 
such as diagnostic radiology, drawing blood for laboratory values and toxicological 
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screening, etc.  Once the diagnosis is determined, the emergency department (ED) 
physician develops a treatment plan for the patient, which may include decontamination 
of the body, stabilization, prevention of continued absorption, the use of an antidote, 
supportive care and monitoring.  ED physicians rely on various resources to design a 
treatment plan for patients based on symptoms of toxicity.  In an acute care situation, 
being able to access relevant information and get real-time answers tailored to individual 
patients’ needs are essential to patient survival.   
2.2 Medical algorithms 
A medical algorithm is any formula, look-up table, nomogram, graph, flowchart, or 
computation that supports medical decision-making [19].  Medical algorithms assist in 
the improvement and standardization of healthcare.  Medical algorithms are not 
necessarily computerized and can often be represented in paper form.  However in the 
U.S., as new regulations concerning electronic record-keeping and meaningful use 
measures are being implemented, the requirements are clearly beginning to incorporate 
computational medical algorithms into electronic health record systems (EHR) [20].  
Some of the new requirements incorporating medical algorithms include electronically 
identifying diagnostic or therapeutic references triggered by lab values or vital signs, 
drug-drug interaction checks, and drug-allergy interaction checks.   
Medical algorithms are used extensively in healthcare.  They are used in diagnosis, 
therapeutic selection, disease outcome prediction and medical machinery automation.  
There are several motivating factors for implementing medical algorithms – higher 
quality healthcare, more efficient delivery of healthcare, cost reduction, safer healthcare 
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delivery, standardization of healthcare and improved healthcare outcomes [19].  Medical 
algorithms aid healthcare in the move towards the standardization of medicine based on 
best practice evidence or a concept called evidence based medicine (EBM).  The EBM 
movement was born out of a concern that inadequate medical therapy being delivered 
was based on conventional practices, clinical intuition, and practitioner bias rather than 
scientific evidence [21]. 
2.3 Clinical Decision Support Systems (CDSS) 
Clinical decision support systems are software designed to be a direct aid to clinical 
decision-making.  CDSS match the characteristics of an individual patient to a 
computerized clinical knowledge base and present patient-specific assessments or 
recommendations to the clinician or patient for decision-making purposes [22].  There are 
a number of systems that have been implemented for a wide variety of clinical issues 
such as diagnostic systems, reminder systems, disease management systems, and drug 
dosing or drug prescribing systems [23-26].  Garg et al. reported that many of these 
systems improve the performance of practitioners [27]. 
In terms of drug selection systems and dose recommendation systems, there is limited 
data on their effectiveness in clinical practice.  Yet, research into drug selection systems 
has been in progress for over 40 years.  In 1973 Shortliffe described an artificial 
intelligence system that assists practitioners in the selection of an appropriate antibiotic 
[28].  In 1996 a study was performed to evaluate a system that suggested a cheaper 
alternative medication if available.  Compliance was extremely low with only 2.8% of the 
prescriptions wrote by the physicians being recommended by the system during the study 
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[29].  Physicians in the study complained of a high rate of downtime, slow data retrieval, 
network instability and system failures. Several dose recommendation systems have been 
described such as the GRIP insulin dose recommendation system, which has achieved 
excellent results in blood glucose control in intensive care units [30, 31].  Though CDSS 
in medicine have not been overly successful in diagnosis, a significant level of 
improvement has been shown with CDSS in drug dosing or prescribing [27].  There have 
been quite a few studies in computer assisted anticoagulant dosing that have 
demonstrated effective decision support capacity [32-35].  Though further studies on 
other medication dosing systems have been performed, most have only been designed for 
medications with a narrow therapeutic index like the insulin and anticoagulant studies 
described above.   
2.4 Overview of Expert and Clinical Decision Support Systems in Toxicology 
Medical practitioners in U.S. health care facilities have several tools that assist in the 
treatment of exposures to toxins. Antidote charts, toxicology texts, electronic toxicology 
databases and toxicology decision support systems provide exhaustive discussions of the 
treatment of toxic exposures. We reviewed 14 electronic toxicology databases and 3 
quick reference antidote charts as shown in Table 2 based on the below six criteria: 
1) Is the system available offline and/or online? 
2) Does it provide patient specific dose calculations? 
3) Does it provide patient specific treatment recommendations? 
4) Is it exclusively for Toxicology (poisoning and overdose)?  
5) Is it linked to Poison Control and FAER?  
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6) Is it well referenced?  
Table 2.1 Clinical Decision Support Drug Databases in Toxicology. 
 Name 
Available 
Offline 
Available 
Online 
Patient-
Specific 
Dose 
Calculations 
Patient 
Specific 
treatment 
suggestions 
Toxicology 
Exclusive 
Linked 
to 
Poison 
Control 
and 
FAER 
Refer- 
ences 
1. ATSDR [36] No Yes No No Yes No Yes 
2. 
Clinical 
Pharmacology 
[6] 
No Yes 
Calculators 
Not patient-
specific 
No No No Yes 
3. 
Epocrates® 
[37] 
Yes No No No No No Yes 
4. 
Facts & 
Compari-
sons® [38] 
Yes (in 
print) 
Yes No No Yes No Yes 
5. GlobalRPh No Yes Only one Only one No No Yes 
6. 
LexiComp® 
Online™ 
-LexiTox 
Module [39] 
Yes Yes 
Calculators 
Not patient-
specific 
No Yes No Yes 
7. 
Medline® 
Plus [7] 
No Yes No No No Yes Yes 
8. 
Medscape 
[40] 
Yes Yes 
Calculators 
Not patient-
specific 
No Yes No Yes 
9. 
Micro- 
medex® 2.0 
[41] 
No Yes 
Calculators 
Not patient-
specific 
No Yes No Yes 
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10. Pepid™  [42] No Yes 
Calculators 
Not patient-
specific 
No Yes No Yes 
11. RxList [43] No Yes No No No No Yes 
12. 
SkyScape® 
Archimedes 
[44] 
Yes No 
Calculators 
Not patient-
specific 
No No No Yes 
13. ToxNet [45] No Yes No No No No Yes 
14. OpenTox [46] No Yes No No Yes No No 
15. 
California 
Poison 
Control 
Antidote 
Chart [8] 
Yes No No No Yes No Yes 
16. 
Oklahoma 
Poison 
Control 
Antidote 
Chart [9] 
Yes No No No Yes No No 
17. 
2012 Antidote 
Chart[47] 
Yes No No No Yes No Yes 
 
The Agency for Toxic Substances and Disease Registry (ATSDR), an agency of the U.S. 
Department of Health, maintains an online electronic reference database on toxic 
substances and in some cases provides information on treatment of exposure or overdose.  
ATSDR has neither automated clinical decision support, nor an electronic dose calculator 
for antidotes [36]. 
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Clinical Pharmacology is a subscription-based online drug information database. Its 
primary focus is on general drug information.  However, it does provide a clinical 
reference module for identification, diagnosis and therapy-management of drug and 
poisoning emergencies called ToxEd.  It does not support electronic dose calculations for 
antidotes.  Though it purports its reference as a clinical decision support mechanism, it 
does not appear to be automated in any way [6].   
Epocrates® is an electronic drug information database available online and as a mobile 
application. The downloadable mobile application is available offline.  Both are available 
free of charge.  Epocrates® offers no central toxin or antidote database, though all 
antidotes are listed in their pharmaceutical database.  It provides neither automated 
clinical decision support nor electronic dose calculator for antidotes [37]. 
Facts and Comparisons® (F&C) is a subscription-based electronic and print drug 
information database. While the print version of F&C is available offline, the electronic 
version requires Internet access.  F&C offers an add-on toxicology treatment guideline 
module as a supplement to their database.  It provides neither automated clinical decision 
support nor electronic dose calculator for antidotes [38]. 
GLOBALRPh, a website with a collection of pharmaceutical reference tools, hosts a 
large number of calculators. Among them, there is only one calculator relevant to the 
treatment of toxin overdose, the dose calculator for ethylene glycol toxicity 
(http://www.globalrph.com/ethanol.htm).  The calculated dosages are embedded in the 
text description of the treatment recommendation.  As GLOBALRPh does not focus only 
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on the treatment of toxin overdose, the ethylene glycol toxicity calculator is buried 
among many other non-toxicology related calculators and not very visible [48]. 
Lexicomp® offers an online drug information database and a mobile application.  The 
mobile application is available offline.  Both are available as subscription-based entities.  
Lexicomp® offers a toxicology database and dosing reference named Lexi-Tox™.  Lexi-
Tox™ has no automated clinical decision support.  Lexi-Tox™ is linked via Lexi-Calc™ 
to a limited number of antidote dose calculators including, acetylcysteine, ethanol, and 
fomepizole. Dosages are not integrated into the text of a treatment recommendation as 
with GlobalRPh.  We found that Lexicomp has consistently provided the most accurate 
and up to date evidence based drug information [39].   
MedlinePlus®, an online drug information database, is a service of the U.S. National 
Library of Medicine.  The information is geared for a nonclinical audience.  The service 
is also available free of charge.  It provides neither automated clinical decision support 
nor electronic dose calculator for antidotes [7].  
Medscape is a subsidiary of WebMD, which is a free online health database for the 
general consumer market.  Medscape is designed for the clinical audience and offers a 
free online antidote reference database and a few limited calculators.  The calculators do 
not appear to have been properly tested however, as at least one of them – leucovorin - 
contains a serious error.  This was pointed out via an online feedback form to which there 
was no reply.  Dosage ranges are suggested within the text of treatment recommendations 
some of which have a link to run a script for dose calculation [40].   
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Micromedex® 2.0 offers a toxicology database and a solution that calculates the proper 
antidote dose of ethanol for methanol and ethylene glycol overdose, and acetylcysteine 
for acetaminophen overdose.  It provides no automated patient specific treatment 
recommendations [41].  
Pepid™ knowledgebase offers a comprehensive antidote reference for identification and 
treatment of toxicology emergencies.  Pepid™ does incorporate several dose calculators 
sporadically into its drug reference text (acetylcysteine, deferoxamine, dimercaprol, 
flumazenil, fomepizole, methylene blue, d-penicillamine, sodium bicarbonate, and 
succimer).  However, as with some of the above-mentioned systems, the list of antidotes 
covered by Pepid™ is incomplete. In addition, the dose calculators do not cover all 
dosing scenarios.  Last, there is no dedicated clinical decision support mechanism that 
generates automated treatment recommendations and patient-specific antidote dose 
calculations.[42] 
RxList is a free online drug information database. The target audience, much like 
MedlinePlus, is the general public.  One major difference between the two is that the U.S. 
Federal government funds MedlinePlus, while corporate sponsors fund RxList. It 
provides neither automated clinical decision support nor electronic dose calculator for 
antidotes [43]. 
Skyscape® is a mobile electronic drug database.  It provides a reference database for 
poisoning and drug overdose.  Though it does have many calculation functions, it has no 
automated antidote calculator module [44].   
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Toxnet, managed by the U.S. Library of Medicine, is a repository of databases on 
toxicology, hazardous chemicals, environmental health, and toxic releases.  Toxnet is 
mainly a reference database, as it has neither electronic automated clinical decision 
support nor an electronic dose calculator.  Its target audience is the general public [45]. 
Several expert systems in toxicology have been developed. In 1985, Rubens described a 
rule-based system that focuses on an in-home first response algorithm for children 
[49].  In 1994 Darmoni and coauthors described an expert system in toxicology 
developed for a regional hospital in France which focuses largely on diagnosis of 
poisoning arising from the medication overdose and gives general treatment 
recommendations with no patient specific dose calculations [50].  Most recently, in 2010, 
a group in Malaysia developed a system that focuses on poisoning diagnosis [51]. 
However none of the three above-mentioned expert systems are publically available for 
review.   
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3 MATERIALS AND METHODS 
3.1 Introduction 
In total, we implemented 27 algorithms for the treatment of common toxin exposure in 
the AA. Several representative algorithms are introduced in this chapter and the 
remaining ones are covered in Appendix A.  The list of antidotes used, as shown in Table 
1.1, is derived from an expert panel consensus document published in the Annals of 
Emergency Medicine in 2009 that recommends antidote formulary inclusions for 
hospitals [12]. The formulary antidote recommendations are specifically for North 
American Hospitals.  
For dose calculations, the FDA approved dosing guidelines published by the 
manufacturers were used, whenever available. However, not all antidotes described by 
the expert panel had approved FDA indications [5]. The reason for this is that some 
antidotes have been “grandfathered” as accepted antidotes after the FDA began to require 
an approval process.  Further, as with most antidotes or medications there are few studies 
on infants and children.  Also, at times the FDA approved indications can be so broad 
that there is debate on whether or not toxicity is and approved indication (see calcium 
chloride and calcium gluconate in Appendix A).  For treatment of those antidotes, several 
off-label or yet unapproved-use algorithms reported in primary literature references were 
used.  We tried our best to avoid using tertiary literature because the survey of 17 major 
sources (see Table 2.1) during this project yielded inconsistencies in treatment 
recommendations. Each algorithm in the AA is clearly labeled for its FDA approval 
status.  There are three antidotes that have unapproved indications:  ethanol for methanol 
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and ethylene glycol poisoning, glucagon for calcium-channel/beta blocker overdose, and 
octreotide for hypoglycemia secondary to sulfonylurea overdose.  The approval status of 
calcium chloride and calcium gluconate in the treatment of fluoride and calcium channel 
blocker overdose is questionable due to the broad language of the approved indication.  
See calcium chloride and calcium gluconate in Appendix A. 
Algorithms are verified using the drug dosing treatment guidelines found in the FDA 
approved antidote’s drug monographs when available.  In addition, we have implemented 
more advanced treatment guidelines as they became available.  If no drug monograph is 
available to verify an antidote algorithm, guidelines from primary literature are obtained.  
At times tertiary literature has proven useful in identifying current primary literature 
sources as well as suggesting sources for good current practice guidelines.   
Once an algorithm verified, each permutation of the treatment is determined. Each 
antidote algorithm has distinct characteristics such as the indication, treatment thresholds, 
or hypersensitivity, which are specifically related to the treatment recommendations and 
dose calculations. All of these factors must be considered when determining the correct 
permutation of treatment and dose calculation for each individual patient.  
Some medical antidotes described in the AA are used in multiple algorithms.  These 
antidotes have multiple indications and can be used under more than one poisoning 
scenario.  For example, dimercaprol is used in two algorithms.  First, it is used in tandem 
with Ca-EDTA in the treatment of lead poisoning.  Second, it is used in the treatment of 
heavy metal (arsenic, gold or mercury) toxicity.  At times multiple antidotes are used in 
one algorithm as the treatment of a particular poisoning dictates their concomitant use.  
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One good example is the Cyanide Antidote Package, which uses amyl nitrite, sodium 
nitrite and sodium thiosulfate.  Also, some antidotes may be referred to by another 
algorithm if the antidote used in the algorithm is considered second-line therapy.  
In the AA, the generic and trade names of antidotes follows the medical convention of 
not capitalizing generic names and capitalizing brand names.  For example Tylenol is the 
brand name of acetaminophen.  
Full-scale studies in humans concerning toxicology are scarce due to the nature of the 
problem.  Pursuing human volunteers for poisoning studies would be dangerous to the 
public and highly unethical.  Most primary literature concerning poisoning in humans 
comes from retrospective case studies especially in younger populations.   
We checked primary literature references used by tertiary sources and electronic drug 
databases for treatment algorithms and recommendations.  We found that the references 
in Clinical Pharmacology are often outdated or irrelevant, while those in Lexicomp are 
more useful and up-to-date. To further complicate matters, the published dose 
recommendations sometimes vary from database to database.  This can result in 
inconsistent care among poisoned patients.  Also, errors and ambiguities have been found 
in descriptions of drug administration.  These will be discussed within each algorithm 
description in this chapter. 
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3.2 User input data validation 
To generate patient-specific dosing recommendations, users are required to enter a 
patient’s age, weight, and height in the text boxes on the AA user interface. To minimize 
typographical errors, we implemented several data validation measures.  
First, we implemented numeric data validation so that only numeric data and decimal 
points are allowed.  If any data other than numeric data and decimal points is entered, the 
user is notified that the data is invalid and prompted to enter only numeric values.  As 
shown in Figure 3.1, when “asft” was entered as the patient weight, a warning message 
was shown to inform the user of the error.  In the Java AA, the text boxes are reset after 
the user clicks ok.  The Web AA ensures valid numeric data is to be entered by disabling 
all keyed entry other than numbers and decimal points.    
 
 
Figure 3.1 Screenshot of the Java AA showing a warning message generated by the numeric 
data validation function.  
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Second, to validate the values of a patient’s height, weight, and age to make sure they are 
in reasonable ranges, the user input values are compared to the 2000 CDC Growth Charts 
for the United States: Methods and Development document [52]. Values from the 3rd 
percentile in females (lower limit) to 97th percentile in males (upper limit) were used as 
boundaries for normal range.  Census data for children from 0 to 24 months old had only 
the height in centimeters and weight in kg available.  For all other age groups in the 
Census data the BMI (Body Mass Index) is available.  The age range used to validate 
data is zero (a neonate) to 100 years old.  Figure 3.2 shows the data validation algorithm 
in the form of a flowchart. The data validation subroutine is triggered every time a user 
inputs a set of patient values and clicks one of the begin buttons.  If the BMI calculated 
based on the patient values are not within the 3rd and 97th percentile, the user is given an 
alert that the data is out of range and the option to override the alert or re-enter the data.  
As shown in Figure 3.3 and 3.4, 900kg was entered as the value of patient weight. The 
resulting BMI, when compared to the BMI range from CDC Growth Charts, was flagged 
as out of range.  
The default units for weight and height are kilogram (kg) and centimeter (cm). When a 
user sets the units to pound and inch, the weight and height values are automatically 
converted to corresponding values in kilograms and meters for BMI calculation. The 
BMI is calculated by using the below formula, where W and H denote a patient’s weight 
in kilograms and height in meters.   
BMI = W (kg)/H2 (m2).   
The Body Surface Area (BSA) is calculated based on the Gehan and George formula: 
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𝐵𝑆𝐴 (𝐺𝑒ℎ𝑎𝑛 𝑎𝑛𝑑 𝐺𝑒𝑜𝑟𝑔𝑒 𝑓𝑜𝑟𝑚𝑢𝑙𝑎) =  0.0235𝐻0.42246 ∗ 𝑊0.51456 
Where height (H) is in centimeters, and weight (W) is in kilograms [53]. 
The formula used in the calculation of some pediatric dosages is based on the Salisbury 
rule[53]. When a child’s weight (W) is 30kg or less, the dose to be administered is equal 
to 2*W% of the adult dose, according to the Salisbury rule.  If a patient weighs between 
30 to 70 kg, the dose to be administered is equal to (30+W)% of the adult dose. For 
children weighing 70kg or more, the adult dose should be administered. For example if 
the patient weighs 20 kg administer 40% of the adult dose or if the patient weighs 50 kg 
administer 80% of the adult dose.  
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Figure 3.3 Screenshot of the Java AA showing a data out of range message generated by the 
data validation function. 
 
 
Figure 3.4 Screenshot of the Web AA showing a data out of range message generated by the 
data validation function. 
3.3 Treatment Algorithms 
In this section we describe the development of several representative treatment 
algorithms.  The antidote use and FDA approval status is stated.  The toxin’s mechanism 
of action is briefly discussed as well as the antidote’s mechanism of action.  Special 
considerations are described and dosing considerations are explained.  Flowcharts are 
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used to the logic of the algorithm.  All flowcharts are ISO compliant.  The flowcharts 
used to describe the algorithms are based on the ISO compliant flowcharting guidelines 
found in the document IBM Data Processing Techniques [54].  Also, as mentioned in 
Figure 3.2, the variables Age, Height, and Weightkg are in years, centimeters and 
kilograms respectively throughout this document.  In the discussion of methylene blue 
(found in Appendix A) and potassium iodide (found in Chapter 3), children 1 month old 
or less are considered a special population and represented in this way - Age ≤ 0.0833 (1 
month). 
3.3.1 Acetylcysteine (for acetaminophen) 
Acetylcysteine is used in the treatment of acetaminophen (brand name Tylenol®) 
overdose (FDA approved use).  To avoid confusion with the antidote acetylcysteine, the 
shorthand abbreviation of APAP is used to represent the toxin acetaminophen.  In toxic 
concentrations, APAP saturates the glucuronide and sulfate conjugation pathways in the 
liver.  It is then metabolized by the liver isozyme CYP2E1 to a potentially toxic 
intermediate metabolite that is quickly conjugated by hepatic glutathione to a nontoxic 
substance.  As toxicity is sustained, glutathione reserves are depleted and the liver begins 
to build up highly toxic metabolites.  If left untreated, liver dysfunction ensues [55].  
 The mechanism of action for acetylcysteine is to replenish the glutathione reserves by 
acting as a glutathione substitute.  It acts as a protectant until the liver can replenish the 
glucuronide and sulfate pathway reserves [55].  The major factors for developing the 
treatment algorithm for APAP toxicity were weight, APAP blood levels, time the blood 
sample was taken, treatment threshold, and the time of overdose.   
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In 1975 Rumack and Mathew described a treatment threshold for APAP toxicity that is 
represented by the blood concentration in a log-linear fashion over time [56].  In those 
days, concentrations above the Rumack and Mathew line, the dashed line in Figure 3.2, at 
any given time between 4 and 24 hours after APAP exposure were consistent with 
overdose.  Liver dysfunction does not become noticeable until 4 hours after exposure to 
APAP.  Blood concentrations taken earlier than 4 hours post exposure can yield a false 
negative result [56-58]. In 1976 the FDA defined the treatment line that was 25% below 
the Rumack and Mathew line [58] (see Figure 3.5). The treatment line, starting at 
150mcg/ml at 4 hours, is used in the U.S. hospitals to determine treatment of 
acetaminophen overdose.  It was noted that doses above 4 grams/day in adults and 
accordingly smaller doses in children have a high correlation with liver damage. 
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Figure 3.5 Acetaminophen overdose nomogram (adapted from Temple and Baggish) [57]. 
To automate the process of determining treatment threshold at a specific time point, we 
derived mathematical equations based on the nomogram.  Using two points on the 
treatment line (150mcg/ml at 4hrs and 37.5mcg/ml at 12hrs), we were able to use a 
pharmacokinetic first order rate equation to calculate the elimination rate constant.  The 
following illustrates how the rate constant was derived.  
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−
𝑙𝑛
𝐶𝑡
𝐶0
∆𝑡
=  𝑘                                                           (4) 
𝑘 =  −
𝑙𝑛
37.5 𝑚𝑐𝑔
150 𝑚𝑐𝑔
8ℎ𝑟
                                                     (5) 
𝑘 =  0.17329 ℎ𝑟−1                                                   (6) 
 𝐶0 𝑎𝑛𝑑  𝐶𝑡 denote the APAP plasma concentration at 4 hours post exposure and at time 
point t respectively, ∆𝑡 denotes the time elapsed from 4 hours post ingestion to time point 
t, and k represents the elimination rate constant.  
Next we calculate plasma threshold at a time ≥ 4 hours post APAP ingestion using the 
first order rate equation. It is compared to the APAP plasma concentration of the patient 
to determine if treatment is indicated.  
If the APAP blood concentration observed at time point t (in hours post ingestion) is ≥
 (150𝑚𝑐𝑔/𝑚𝑙)𝑒− (0.17329)(𝑡− 4ℎ𝑜𝑢𝑟𝑠), then treatment is indicated.  For example an APAP 
concentration of 135mcg/ml at 5 hours post exposure is above the treatment threshold 
(150𝑚𝑐𝑔/𝑚𝑙)𝑒−(0.17329)(5 ℎ𝑜𝑢𝑟𝑠− 4ℎ𝑜𝑢𝑟𝑠), or 126mcg/ml.  Thus acetylcysteine therapy is 
indicated. 
Oral dosing for acetylcysteine includes a loading dose of 140mg/kg PO once followed by 
70mg/kg every 4 hours for 17 doses.  Intravenous dosing includes 150mg/kg (maximum 
of 15000mg) IV over 60 minutes followed by 50mg/kg (maximum 5000mg) IV over four 
hours followed by 100mg/kg (maximum 10000mg) IV over 16hours.  
It is also suggested that activated charcoal be administered orally to patients within 4 
hours of suspected overexposure to APAP.  This prevents further gastrointestinal 
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absorption of APAP.  Administration of activated charcoal 4 or more hours after 
exposure has little to no benefit [57].  
In the algorithm that we developed, there are six possible outcomes as shown in Figure 
3.6.  The Data Validation flowchart in Figure 3.1 connects to the flowchart in Figure 3.6 
A.   
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A) Acetylcysteine algorithm. 
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B) Acetylcysteine subroutines. 
Figure 3.6 Acetylcysteine algorithm and subroutines. 
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3.3.2 Black Widow (Latrodectus Mactans) Antivenin 
Antivenin (LATRODECTUS MACTANS) (Black Widow Spider Antivenin) Equine 
Origin (BWAV) is used in the treatment of symptoms caused by Black Widow spider 
bites (FDA approved).  Black Widow venom is a neurotoxin affects myoneural junctions 
or nerve endings.  It can cause motor paralysis or destruction of peripheral nerve endings 
depending on the site of the bite.  The BWAV mechanism of action is unknown and there 
is no human pharmacokinetic or metabolic data [59].  BWAV is derived from horse 
serum and can cause sensitivity reactions.  For that reason, a sensitivity test should be 
performed prior to administration.  Also, if the patient is sensitive to the antivenin, a 
desensitization protocol must be used for administration.  The flowchart in Figure 3.7 
summarizes the treatment algorithm (for brevity the sensitivity test is not included in the 
flowchart). One vial (6000 units) of BWAV should be administered to both adults and 
children either IV or IM.  IV is preferred in children under 12 and in severe cases.  For 
patients with mild symptoms aged 16 to 60 years (16≤age≤60), it is recommended that 
the patient heal naturally [59]. 
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3.3.3 Botulism Antitoxin (Non-Infant) 
Botulism Antitoxin (Non-Infant) or BAT is used for the treatment of symptomatic or 
confirmed exposure to botulism neurotoxins (BoNT) A, B, C, D, E, F, or G (FDA 
approved) [60].  Botulism manifests in two pathways, foodborne botulism and infections 
as a result of toxin formation from spores in vivo.  Infant botulism is the most common in 
the 2nd pathway as infants are unable to combat ingested live bacteria, as their immune 
system is too immature.  Foodborne botulism is the result of ingesting food containing 
large quantities of BoNT.  BoNT impairs synapses dependent upon acetylcholine in the 
peripheral nervous system [55].  BAT’s mechanism of action is to immunize against the 
BoNT passively with equine antibody fragments [60].  As BAT is of equine derivation, 
there is the possibility of sensitivity. A sensitivity test should be performed prior to 
administration.  Other significant factors in creating the BAT algorithm include age and 
weight.  As shown in Figure 3.8, dosing recommendations for BAT include one vial BAT 
for Adolescents and Adults ≥ 17 years.  Doses are calculated using the Salisbury rule 
(See Figure 3.13) in children and adolescents 1-year or older and younger than 17 
(1≤age<17).  For infants younger than 1 year of age, administer 10% of one vial 
regardless of body weight [60]. 
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3.3.4 Botulism Immune Globulin-Infant (BabyBIG) 
BabyBIG is used in the treatment of infant BoNT A or B exposure (FDA approved) [61].  
It is human derived from the plasma of adults immunized with BoNT A and B.  The 
mechanism of action of BabyBIG is to provide enough antibodies to neutralize 
circulating BoNT.  Though the possibility of sensitivity exists with any medication, 
BabyBIG is human derived and a sensitivity test is not recommended.  It is indicated in 
infants younger than 1 year of age (age<1), not in patients aged 1-year or older.  
BabyBIG is given 50mg/kg as a single dose (Figure 3.10) [61]. 
 
Figure 3.10 Botulism Immune Globulin (infant) algorithm. 
3.3.5 Deferoxamine (for acute iron toxicity) 
Deferoxamine is used in the treatment of acute iron toxicity (FDA approved) [62].  In 
iron toxicity, high concentrations saturate transferrin (the iron transport) and “free” iron 
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becomes absorbed by many organ systems.  Iron disrupts mitochondrial phosphorylation 
and causes metabolic acidosis.  Iron also has a direct negative effect on myocardial 
contractility.   
Deferoxamine forms a complex with ferric (trivalent) ions to form ferrioxamine, which is 
removed renally [55, 62].  The significant factors in developing the deferoxamine 
algorithm include cardiovascular collapse (shock), age and weight.  In dosing 
deferoxamine there is some confusion about the best route of administration.  The 
product package insert states that only in cases of shock should deferoxamine be given IV 
[62].  However, in Goldfrank’s the author states that IM is an antiquated route of 
administration and should only be used when IV access is not possible [55].  The FDA 
has approved the package insert for deferoxamine, not Goldfrank’s monograph on 
deferoxamine.  For that reason we implemented the package insert recommendations.  As 
shown in Figure 3.11, for adult patients in shock (age>18), give 1g deferoxamine IV at a 
rate of 15mg/kg/hr followed by 500mg deferoxamine IV every 4 hours for two more 
doses.  For children 3-years or older and younger than 18 (3≤age<18), give 40 to 
90mg/kg IV up to 1000mg at a rate of 15mg/kg/hr followed by 40 to 90mg/kg IV up to 
1000mg every 4 hours for two more doses.  Depending on the patient’s response, further 
doses every 4 to 8 hours for 24 hours may be administered with total a dose not 
exceeding 6 grams.  Safety and efficacy has not been established in children younger than 
3 years of age and is not recommended. 
For iron toxic patients not in shock, the same schedule should be followed via 
intramuscular route [63].   
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3.3.6 Naloxone 
Naloxone is used in the treatment of known or suspected opioid overdose [55, 64].  When 
we use the term opioid in this discussion we mean opiates and opiate-like substances.  
Opioid substances bind opioid receptors in the body and produce several beneficial 
effects - most notably analgesia.  Other effects that become significant in toxicity include 
respiratory depression, cardiovascular changes and seizure.  Naloxone is a pure opioid 
receptor antagonist and completely reverses the effects of all opioids with the exception 
of buprenorphine [55, 64].   
Factors that affected the development of the naloxone algorithm included age, weight, 
and type of intravenous administration – IV bolus or IV continuous-infusion (IVCI).  IV 
dosing of naloxone is summarized in Figure 3.12.  For patients older than 18 years 
(age>18), give 0.4 - 2mg naloxone IVP.  Dose may be repeated every 2-3 minutes up to 
10mg.  IVCI dosing for patients older than 18, start naloxone 0.4-0.8mg/hr IVCI and 
titrate to response [64].   
For patients 18 or younger and 5-years or older (5≤age≤18), or weighing more than 20 
kg, give naloxone 2mg IVP every 2-3 minutes as necessary (max 10mg total).  IVCI 
dosing in the same group starts with 0.4-0.8mg/hr of naloxone IVCI and titrate to 
response [65, 66].   
For patients 18-years or younger and 5-years or older (5≤age≤18), or weighing 20 kg or 
less, give 0.1mg/kg IVP up to 2mg may repeat dose if necessary.  For IVCI in this group 
give 0.04-0.16mg/kg/hr of naloxone IVCI and titrate to response[65, 66]. 
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3.3.7 Potassium iodide 
Potassium iodide (KI) is used to block the absorption of radioactive iodine in patients that 
have been exposed in a non-therapeutic setting (iodine-131 is used for ablating cancerous 
thyroid tissue) [55, 67].  All isotopes of iodine are readily absorbed by thyroid tissue. 
Radioactive iodine (I-131) is a particulate emitter and the absorbed dose can destroy 
thyroid tissue.  Radioactive iodine can also have latent carcinogenic effects on the 
surrounding tissue much like any other radioactive substance.  KI saturates the iodine 
receptors in the thyroid, which competes with radioactive iodine and significantly reduces 
uptake [55].   
Significant factors in developing the KI algorithm include age, pregnancy status and level 
of radiation exposure.  The suggested dosing schedule of KI, as shown in Figure 3.13, is 
as follows:  Patients 0.0833 years (1 month) or younger (age<0.0833) should receive 16.5 
mg PO daily for exposure ≥ 5cGy.  Patients 3-years or younger and older than 0.0833 
years (0.0833<age≤3) should receive 32.5mg PO daily for exposure ≥ 5cGy.   Pregnant 
or breastfeeding patients should receive 130mg PO for exposure ≥ 5cGy.  Patients 12-
years and younger, yet older than 3 (3<age≤12), should receive 65mg PO daily for 
exposure ≥ 5cGy.  Patients 18-years or younger, yet older than 12 (12<age≤18), should 
receive 65mg (weight less than 68kg) or 130mg (weight greater than or equal to 68kg) 
PO daily for exposure ≥ 5cGy.  Adults 40-years or younger and older than 18 
(18<age≤40), should receive 130mg PO daily PO daily for exposure ≥10cGy.  Adults 
older than 40 years of age (age>40) should receive 130mg PO daily PO daily for 
exposure ≥ 500cGy [68]. 
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In this chapter we discuss the implementation of the standalone downloadable application 
(Java AA) and the online web Antidote Application (Web AA).  We also discuss several 
case studies of algorithm implementation - the acetylcysteine algorithm, which is one of 
the most complicated algorithms, the Black Widow antivenin algorithm, the Botulism 
Antitoxin (BAT) algorithm used for food poisoning in adults and children, the Botulism 
Immune Globulin – infant (BabyBIG) algorithm for treatment of infant botulism 
infection, the deferoxamine algorithm used in the treatment of iron poisoning or chronic 
iron toxicity in sickle cell or dialysis patients, the naloxone algorithm that is important in 
common medical practice for the reversal of opioid effects,  and the potassium iodide 
algorithm due to the growing threat of the use of radioactive materials in warfare and 
terrorist acts.  
3.4 Implementation 
In this section we summarize the key factors considered when choosing the programming 
language and architecture of the Java AA and Web AA.  The Java AA may be 
downloaded from the Antidote Application homepage at http://projects.met-
hilab.org/antidote/.  In the Mac and Windows OS, once downloaded the application may 
be ran by right clicking on the antidote_application.jar file in Finder.  The security 
settings in the Mac and Windows OS will alert the user that the application is from an 
unidentified developer.  Click open and the application will begin.  The Web AA can be 
used directly from the website (http://projects.met-hilab.org/antidote/) by following the 
instructions.  
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3.4.1 Standalone downloadable AA implementation  
When considering a programming language for the standalone Antidote application, Java 
was an immediate favorite.  There are a number of features that Java offers that are of 
great benefit to the AA.  Java is platform independent, which means the code, can be 
written once and used on many different operating systems.  Java programs are runnable 
on the Windows, Apple, and Linux operating systems.  Java is also object oriented, which 
allows code to be reused by other programs.  This is of significant advantage and is used 
extensively in the Java AA.  The parent Antidote class is a repository for many pieces of 
code used throughout the many child classes of the Java AA.  For example the code for 
calculating doses based on body surface area (BSA) is located and called from the 
Antidote class.  Java is relatively easy to learn and maintain.  Since Java has a minimal 
number of keywords that are in natural-language syntax, Java is simpler to learn than 
some other languages.  Also, as Java applications do not need to be rewritten for different 
platforms or operating systems, maintenance updates are easier to implement.  Android, a 
mobile operating system is also based on Java.  This is important as we plan to extend the 
AA project in the mobile application sphere.  
The structure of the Java AA was kept very lean and simple.  There is a parent class 
known as the Antidote class.  The Antidote class contains instance variables and methods 
that are inherited by all of the child classes.  The 27 child classes include the instance 
variables (attributes) and methods specific to each antidote algorithm described in 
Chapter 3 and Appendix A.  The graphical user interface class controls the flow of 
information between the user and the Java AA.  The UML (Unified Modeling Language) 
diagram in Figure 4.1 shows this relationship. 
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4 RESULTS  
In this chapter we discuss the implementation of the standalone downloadable application 
(Java AA) and the online web Antidote Application (Web AA).  We also discuss several 
case studies of algorithm implementation - the acetylcysteine algorithm, which is one of 
the most complicated algorithms, the Black Widow antivenin algorithm, the Botulism 
Antitoxin (BAT) algorithm used for food poisoning in adults and children, the Botulism 
Immune Globulin – infant (BabyBIG) algorithm for treatment of infant botulism 
infection, the deferoxamine algorithm used in the treatment of iron poisoning or chronic 
iron toxicity in sickle cell or dialysis patients, the naloxone algorithm that is important in 
common medical practice for the reversal of opioid effects,  and the potassium iodide 
algorithm due to the growing threat of the use of radioactive materials in warfare and 
terrorist acts.  
4.1 Implementation 
In this section we summarize the key factors considered when choosing the programming 
language and architecture of the Java AA and Web AA.  The Java AA may be 
downloaded from the Antidote Application homepage at http://projects.met-
hilab.org/antidote/.  In the Mac and Windows OS, once downloaded the application may 
be ran by right clicking on the antidote_application.jar file in Finder.  The security 
settings in the Mac and Windows OS will alert the user that the application is from an 
unidentified developer.  Click open and the application will begin.  The Web AA can be 
used directly from the website (http://projects.met-hilab.org/antidote/) by following the 
instructions.  
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4.1.1 Standalone downloadable AA implementation  
When considering a programming language for the standalone Antidote application, Java 
was an immediate favorite.  There are a number of features that Java offers that are of 
great benefit to the AA.  Java is platform independent, which means the code, can be 
written once and used on many different operating systems.  Java programs are runnable 
on the Windows, Apple, and Linux operating systems.  Java is also object oriented, which 
allows code to be reused by other programs.  This is of significant advantage and is used 
extensively in the Java AA.  The parent Antidote class is a repository for many pieces of 
code used throughout the many child classes of the Java AA.  For example the code for 
calculating doses based on body surface area (BSA) is located and called from the 
Antidote class.  Java is relatively easy to learn and maintain.  Since Java has a minimal 
number of keywords that are in natural-language syntax, Java is simpler to learn than 
some other languages.  Also, as Java applications do not need to be rewritten for different 
platforms or operating systems, maintenance updates are easier to implement.  Android, a 
mobile operating system is also based on Java.  This is important as we plan to extend the 
AA project in the mobile application sphere.  
The structure of the Java AA was kept very lean and simple.  There is a parent class 
known as the Antidote class.  The Antidote class contains instance variables and methods 
that are inherited by all of the child classes.  The 27 child classes include the instance 
variables (attributes) and methods specific to each antidote algorithm described in 
Chapter 3 and Appendix A.  The graphical user interface class controls the flow of 
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information between the user and the Java AA.  The UML (Unified Modeling Language) 
diagram in Figure 4.1 shows this relationship. 
 
Figure 4.1 Antidote Application UML diagram. 
When the Java AA is initiated, the antidote GUI interface is called and the user is 
presented with the main page of the program and prompted to enter the patient’s age, 
weight, and height.  The user is also prompted to select the algorithm of interest by 
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choosing an antidote or the corresponding toxin if the user knows the cause of toxicity 
but unsure of the antidote.  After user input data from the GUI is validated as described in 
section 3.1, the appropriate antidote class is called from the antidote class library.  Any 
alerts or messages concerning the algorithm that need to be conveyed or if further data is 
required from the user, JOptionPane message or input windows are used from the 
javax.swing package.  The return output in the form of a string is displayed in the text 
area of the GUI.  At any point in time the user can select an antidote from the antidote 
dropdown scrollbar and click the references button to view the references of that 
particular antidote algorithm.  
4.1.2 Web-based Antidote Application 
The Web AA user interface, calculations and recommendations parallel the Java AA.  
However the language and structure of the Web AA is quite different.  Several web 
development technologies such as JavaScript, jQuery, HTML, CSS, Ajax, and AngularJS 
were employed.  It is a client-side application, meaning that all computations are 
processed on the client’s computer.  The Web AA uses a Model-View-Controller (MVC) 
architecture, a software architectural pattern for implementing user interfaces. It divides a 
software application into three interconnected parts - the model consists of the application 
logic, the controllers are responsible for manipulating data, and views present the data 
generated by the user inputs and controller/model outputs.  In the Web AA the model 
consists of the antidote algorithms, the views are the graphical representations, the 
controller manipulates the model and the view.  The controller passes user inputs from 
the view to the model (antidote algorithms) and communicates the model outputs to the 
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user.  The separation into these distinct entities improves the extensibility and 
maintainability of the Web AA.  Figure 4.2 is a graphical representation the MVC 
relationship. 
 
Figure 4.2 Architectural data flow diagram of Web AA (Courtesy of Yingyuan Zhang). 
 
4.2 Main pages of the AA 
The main page of the Java AA is divided into three sections; upper, middle, and bottom 
by two horizontal dividers in black color as shown in Figure 4.3.  
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Figure 4.3 Screenshot of Java AA main page. 
The upper section consists of four columns each with three cells.  The first column of 
cells on the left contains labels for user input areas in the second column – the age, 
weight, and height.  The cells in the second column are text fields for user input of age 
weight and height. In the third column there are cells containing dropdown menus where 
the user can toggle between years or months for the age input, kilograms or pounds for 
weight input, and centimeters or inches for height.  In the last column there are text fields 
for the BMI and BSA display, and a button for the specific antidote references.  The BMI 
and BSA are calculated and displayed each time an algorithm is ran.  The references 
button display the literature references for each specific algorithm.   
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In the middle section, there are three columns with two cells each.  The first column on 
the left contains the labels and instructions for the two drop-down menus in the 2nd 
column, antidote and toxin.  In the second column, the dropdown menus for antidotes and 
toxins have the most commonly used names for the antidotes and toxins with brand 
names capitalized and generic names in lower case.  To run an algorithm, select an 
antidote or a toxin from the corresponding drop-down menus and click on “Begin 
Antidote Algorithm” or “Begin Toxin Algorithm”.  The bottom section contains a single, 
resizable text area.  When the AA is first launched, the text area displays the disclaimer, 
the national toll-free number to Poison Control, the URL to the Federal Adverse Event 
Reporting system (FAER), and brief instructions on the use of the AA.  The reporting of 
adverse events to the FAER is voluntary.  When an algorithm is run, the text area is 
where its output is displayed.   
The main or home page of the Web AA has a few differences as shown in Figure 4.4. 
First, the Boston University (BU) Metropolitan College (MET) Health Informatics Lab 
logo locates in the top left corner and the navigate bars hyperlinked to Home, Antidote, 
Toxin, and FAQ pages are in the top right corner.  Different from the Java AA, the 
selection of the toxin and antidote are located in two separate pages in the web AA.  On 
the homepage below the title “Antidote Web Application”, there is a paragraph 
describing the Antidote Application project followed by a disclaimer stating that the AA 
is for educational purposes, the Poison Control phone number, a link to the FAER 
system, and the URL of the standalone downloadable AA.   
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Figure 4.4 Screenshot of Web AA homepage. 
 
On the Antidote or Toxin pages the top half of the page, as shown in Figure 4.5, contains 
the text fields for users to input the age, weight, and height of a patient and the green area 
on the right is for displaying the calculated BMI and BSA.  If a user inputs 40 in the age 
text field, selects year as the unit (Figure 4.5), and later changes the unit to be month, the 
user-input value 40 is converted automatically to 480 months as shown in Figure 4.6.  
Similarly, 193 cm is converted to 75.98 inches and 90kg to 198 lb automatically. 
 
Figure 4.5 and 4.6 are screenshots of the BSA and BMI calculations for an individual that 
is 40 years old, 90 kilograms, and 193 centimeters tall in web AA and Java AA.   
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Figure 4.5 Screenshot of BMI and BSA calculations using web-based AA 
 
 
Figure 4.6 Screenshot of BMI and BSA calculation using Java AA 
If the calculated BMI is out of range, the user is notified as described in section 3.2 data 
validation.   
As mentioned earlier, there is a difference between the Java AA and the Web AA in how 
the antidotes and toxins are chosen.  In the Java AA there are two drop-down menus in 
the middle section of the main page.  The upper is for antidotes and the lower is for 
toxins as shown in Figure 4.7 and 4.8. The Web AA has two separate pages for selecting 
antidote and toxin algorithms as shown in Figure 4.9 and 4.10.  Otherwise the inputs and 
outputs of the Web AA and Java AA are very similar.  In both applications, the drop-
down menus for selecting antidote and toxin are searchable by scrollbar or by typing the 
partial or full name of an antidote or toxin. In the Web AA, as the user types a search 
term, antidote/toxin names that do not match the term are eliminated, leaving the user 
with a shortened list of antidotes or toxins containing the search term as shown in Figure 
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4.11.  In the Java AA the names are retained and the cursor is moved to highlight the 
result.   
 
 
Figure 4.7 Screenshot of Antidote Algorithm drop-down menu. 
 
Figure 4.8 Screenshot of Toxin Algorithm drop-down menu. 
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Figure 4.9 Screenshot of Web AA antidote page and antidote drop-down menu. 
 
Figure 4.10 Screenshot of Web AA toxin page and toxin drop-down menu. 
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Figure 4.11 Screenshot of Web AA when a search term is in the text field of the antidote 
drop-down menu. 
 
The presentation of references for each algorithm differs between the Java AA and the 
Web AA.  In the Java AA, when the user selects an antidote from the antidote drop-down 
menu and clicks “Antidote Reference” button, the corresponding references are displayed 
(Figure 4.12). The references in the Web AA are displayed at the bottom of the result 
page when an algorithm is run  (Figure 4.13). 
 
 
Figure 4.12 Screenshot of BAT references in the Java AA. 
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Figure 4.13 Screenshot of BAT references in the Web AA. 
4.3 Case Studies 
4.3.1  Acetylcysteine 
Acetylcysteine, as discussed in section 3.4.1, is a clinically important antidote.  APAP 
overdose is commonly seen in emergency rooms across the country.  The author – a 
licensed and practicing hospital pharmacist – has received many calls regarding treatment 
recommendations and dosing of acetylcysteine in APAP overdose.  This is due mainly to 
the complexity of determining the treatment threshold and prescribing the appropriate 
treatment regimen. Budnitz et al. reported an average rate of 78,414 emergency 
department visits annually in the U.S. [69].  Most of these non-abuse related visits 
(69.8%) were self-directed violence (suicide attempts).  Often an inexperienced staff 
member will waste valuable time trying to decipher the treatment threshold and 
determine the correct dose and route of administration.  The AA can make individualized 
treatment recommendations based on user inputs.  First the user enters the age, weight, 
and height of the patient, chooses acetylcysteine algorithm and clicks “Begin Antidote 
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Algorithm” button or selects acetaminophen algorithm and clicks “Begin Toxin 
Algorithm” button (Figure 4.14).  Then a series of questions are presented to the user to 
get more specific information (Figure 4.15 A-G). 
 
Figure 4.14 Screenshot of acetylcysteine algorithm initiation. 
 
A) Screenshot of the first question presented to user asking if the time of overdose and 
APAP blood level is known. 
 
B) Screenshot of the second question asking for the time of overdose if user selected 
“Known time of overdose and blood level” in the first question. 
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C) Screenshot of the third question asking how long after the overdose was the blood 
sample was taken if user selected “4 to 24 house ago” in the second question. 
 
D) Screenshot of the fourth question asking for the exact time at which blood sample was 
taken if the user selected “Blood level taken ≥ 4 hours post exposure” in the third question. 
 
E) Screenshot of the fifth question asking the user to input APAP blood plasma level.  
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F) Screenshot of acetylcysteine algorithm output of treatment threshold and whether 
treatment is indicated.  
 
G) Screenshot of acetylcysteine algorithm treatment recommendations and dose 
calculations. 
Figure 4.15 Screenshots of acetylcysteine algorithm. 
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There are multiple response permutations of the acetylcysteine algorithm.  As shown in 
Figure 4.14 the patient is a 40 year-old adult who weighs 90 kg and is 190 cm in height.  
The time of overdose is known to be between 4 and 24 hours post exposure.  The blood 
sample was taken 5 hours after exposure and the APAP blood level is 145 
micrograms/deciliter, which is above the treatment threshold (126.13 
micrograms/deciliter) at 5 hours post exposure.  The scenario described is the most 
complex.  It is also one of the scenarios that have the best possible prognosis since the 
time of overdose is known, between 4 and 24 hours ago, and blood the blood 
concentration of APAP is known.  Treatment recommendations are as follows: 
Acetylcysteine may be dosed intravenously (IV) or orally (PO).  IV Dosing:  13,500 mg 
(not to exceed 15000 mg) IV in 200 ml D5W over 60 min followed by 4,500mg IV in 
500 ml D5W or NS over 4 hours followed by a final dose of 9,000 mg (not to exceed 
10000 mg) in 1000 ml D5W over 16 hours.  Oral Dosing: 12,600 mg PO initially, 
followed by 6,300 mg PO every 4 hours for 17 doses.  Any dose vomited within one hour 
of administration must be repeated.  Blood samples to determine acetaminophen levels 
should be taken no less than 4 hours after acetaminophen overdose for immediate release 
preparations.  Samples taken before this time may not indicate when liver toxicity is 
present.  For extended release preparations, another sample should be taken at 8 hours 
after acetaminophen overdose as these preparations can delay the appearance of toxicity. 
Other permutations include unknown time of exposure (Figure 4.16 A) and exposure less 
than 4 hours ago (Figure 4.16 B), both of which result in similar recommendations.  
Another scenario is when the time of exposure is between 4 and 24 hours ago but the 
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blood sample was taken less than 4 hours after overdose (Figure 4.16 C).    If the time of 
overdose was 4 to 24 hours ago, the blood sample was taken at least 4 hours after the 
overdose, and the APAP blood level is known to be below the treatment threshold, no 
acetylcysteine therapy should be pursued (Figure 4.16 D).  If the time of overdose was 
more than 24 hours ago, acetylcysteine therapy is of little benefit (Figure 4.16 E).  Also, 
there is a recommendation for neonates with weight less than 5kg that suggests a 
neonatologist be consulted and suggests a couple of dose regimens found in primary 
literature for children (Figure 4.16 F).  For patients with overdose occurring less than four 
hours ago, a dose of activated charcoal is recommended based on the patient’s weight in 
addition to acetylcysteine recommendations [57, 70].  
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A) Screenshot of acetylcysteine algorithm treatment recommendations when the time of 
overdose is unknown. 
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B) Screenshot of acetylcysteine algorithm treatment recommendations when the known 
time of overdose is less than 4 hours ago. 
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C) Screenshot of acetylcysteine algorithm treatment recommendation when the known time 
of overdose is between 4 and 24 hours after overdose with blood sample taken less than 4 
hours after overdose. 
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D) Screenshot of acetylcysteine algorithm treatment recommendations when time of 
overdose between 4 and 24 hours after exposure with blood sample taken more than 4 hours 
after overdose and the APAP level below treatment threshold. 
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E) Screenshot of acetylcysteine algorithm treatment recommendations for known time of 
overdose and more than 24 hours after exposure. 
 
F) Screenshot of acetylcysteine algorithm treatment recommendations for patients weighing 
less than 5kg. 
Figure 4.16  Screenshots of acetylcysteine algorithm treatment recommendations and dose 
calculations. 
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4.3.2 Black Widow (Latrodectus Mactans) Antivenin 
Black Widow antivenin is clinically important, mainly from a patient comfort point-of-
view, as most Black Widow envenomations do not result in death.  Most Black Widow 
fatalities result from other underlying issues.  Black Widow antivenin can reduce the 
intensity and duration of pain experienced by the envenomed patient.   
Figures 4.17 A-E show the treatment recommendations for a neonate (age  0.0833 
years), for a child (0.0833<age<12years), for an adolescent patient (12age<16 years), 
for an adult (16age60 years) with severe bite symptoms and for an adult with mild bite 
symptoms respectively.  Please note that the adult (16age60 years) is allowed to heal 
naturally under mild bite conditions, while other patient populations are always treated 
[59].  Figure 4.17 F) shows the treatment recommendation for elderly patients (age>60).  
 
A) Screenshot of treatment recommendations for Black Widow antivenin in a neonate. 
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B) Screenshot of treatment recommendations for Black Widow antivenin in a child. 
 
C) Screenshot of treatment recommendations for Black Widow antivenin in an adolescent. 
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D) Screenshot of treatment recommendations for Black Widow antivenin in an adult with 
severe bite symptoms. 
 
E) Screenshot of treatment recommendations for Black Widow antivenin in an adult with 
mild bite symptoms. 
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 F) Screenshot of treatment recommendations for Black Widow antivenin in an elderly 
patient. 
Figure 4.17 Screenshots of results for Black Widow antivenin algorithm. 
 
4.3.3 Botulism Antitoxin (Non-Infant)  
Botulism antitoxin is clinically significant for its use in neutralizing botulism neurotoxin 
exposure, a relatively frequent form of toxicity in humans.  The results for non-infant 
Botulism Antitoxin (BAT) algorithm are discussed in this section. When the BAT 
algorithm is initiated the user is instructed to perform a skin sensitivity test on the patient 
and input the test result to proceed (Figure 4.18 A).  For infants (age<1), BabyBIG is the 
preferred antidote, however BAT can be used in its absence [60]. (4.17 B and C).  In 
children (1age<17) the dose of BAT is based on the Salisbury rule discussed in section 
3.2  (Figures 4.17 D and E).  Dosing of BAT and treatment recommendations in adults 
are shown in Figures 4.17 F and G.  
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A) Screenshot of BAT algorithm skin sensitivity test. 
 
 
B) Screenshot of BAT algorithm treatment recommendations for infant with no skin 
sensitivity. 
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C) Screenshot of BAT algorithm treatment recommendations for infant with skin 
sensitivity. 
 
D) Screenshot of BAT algorithm treatment recommendations for child (1age<17) with 
no skin sensitivity. 
 
E) Screenshot of BAT algorithm treatment recommendations for child (1age<17) with 
skin sensitivity. 
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F) Screenshot of BAT algorithm treatment recommendations for adult (age17) with 
no skin sensitivity. 
 
G) Screenshot of BAT algorithm treatment recommendations for adult (age≥17) with 
skin sensitivity. 
Figure 4.18  Screenshots of BAT algorithm results. 
 
4.3.4 Botulism Immune Globulin-Infant (BabyBIG) 
BabyBIG is very important to the survival of infants exposed to BoNT.  Infants are not 
able to produce immune responses to ward off the live bacteria that create the botulism 
neurotoxin.  Children and adults have an immune system that is mature enough to handle 
this kind of infection [55, 61].  For this reason, BabyBIG is only indicated in infants 
(age<1 year) (Figure 4.19 A).  The dose and rate in the treatment recommendations for 
infants are based on the patient’s weight as described in section 3.4.4 (Figure 4.19 B).  
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A) Screenshots of BabyBIG algorithm treatment recommendations for patients 1 year 
of age and older.  
 
 B) Screenshot of BabyBIG algorithm treatment recommendations for a one-month-old 
infant with weight 5kg. 
Figure 4.19 Screenshots of BabyBIG algorithm treatment recommendations. 
4.3.5 Deferoxamine (for acute iron toxicity) 
Deferoxamine is used for acute iron toxicity.  It is not indicated in infants and children 
less than three years old (Figure 4.20 A).  Cardiovascular shock determines the route of 
administration, so a question is presented to the user to ask if the patient is in 
cardiovascular shock (Figure 4.20 B). Screenshots have been taken to illustrate various 
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routes of administration, dosages, and the maximum dosages for 24 hours based on 
patients’ weights, cardiovascular states, and age groups.  Children three years of age or 
older but younger than 18 (3age<18) should receive 40 to 90mg/kg of deferoxamine IV 
when in cardiovascular shock or 40 to 90mg/kg of deferoxamine IM when not in 
cardiovascular shock every 4 to 8 hours with the maximum dosage of 6000mg in 24 
hours. Figure 4.19 C, D, and E are the screenshots of treatment recommendations for 
children (3≤age<18) weighing 10kg in cardiovascular shock, for children (3≤age<18) 
weighing 20kg not in cardiovascular shock, and for children (3≤age<18) weighing 30kg 
not in cardiovascular shock respectively. Note that for children (3≤age<18) the maximum 
dose allowed is 1000mg in spite of patients’ weight[62, 63, 71].  Patients 18 years or 
older should receive 1000mg deferoxamine IV when in cardiovascular shock or 1000mg 
deferoxamine IM when not in cardiovascular shock every 4-8hours as needed up to a 
maximum of 6000mg in 24 hours [62, 63, 71] (Figure 4.19 F).  
 
A) Screenshot of deferoxamine algorithm treatment recommendation for infants and 
children less than 3 years. 
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B) Screenshot of cardiovascular shock question. 
 
C) Screenshot of deferoxamine results for children (3age<18) weight 10kg in 
cardiovascular shock. 
 
D) Screenshot of deferoxamine results for children (3age<18) weight 20kg not in 
cardiovascular shock. 
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E) Screenshot of deferoxamine results for children (3age<18) weight 30kg not in 
cardiovascular shock. 
 
F) Screenshot of deferoxamine results for patients aged 18 and older in cardiovascular 
shock. 
Figure 4.20 Screenshots of deferoxamine algorithm results. 
4.3.6 Naloxone 
Opioid overdose is among the top 5 classes of medications that cause emergency adverse 
event visits [72].  Opioid adverse events may be the result of a number of causes.  
Naloxone reverses the effects of opioid agonist overdose and is important in life-threating 
exposures.  In naloxone treatment of opioid overdose, there are two basic methods – IV 
bolus therapy or IV continuous infusion (IVCI).  The method of choice is at the discretion 
of the supervising physician.  Though normally IVCI is used when bolus therapy has 
failed.  For patients with weight 20kg or age 5 year, 0.1mg/kg of naloxone up to 2mg 
per dose should be administered and repeated as necessary for bolus therapy [65, 66] 
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(Figure 4.21 A).  For the same patient population, when using IVCI therapy, 0.04 to 
0.16mg/kg/hr of naloxone should be administered [65, 66] (Figure 4.21 B).  For children 
5 years of age or older but less than 18 years of age and weighing more than 20kg, bolus 
therapy includes 0.4-2mg per dose every 2-3minutes as needed up to 10 mg [65, 66] 
(Figure 4.21 C).  IVCI therapy includes 0.4-0.8mg/hr titrated to desired response (Figure 
4.21 D). For patients over 18 years old, bolus therapy includes 2mg per dose every 2-
3minutes as needed up to 10 mg (Figure 4.21 E) and IVCI therapy includes 0.4-0.8mg/hr 
titrated to desired response [64] (Figure 4.21 F).   
 
A) Screenshot of naloxone algorithm treatment recommendation for a 4-year-old patient 
weighing 21kg with bolus therapy. 
 
B) Screenshot of naloxone algorithm treatment recommendation for a 6-year-old patient 
weighing 19kg with IVCI therapy. 
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C) Screenshot of naloxone algorithm treatment recommendation for a 16-year-old patient 
weighing 60kg with bolus therapy. 
 
D) Screenshot of naloxone algorithm treatment recommendation for a 16-year-old patient 
weighing 60kg with IVCI therapy.  
 
E) Screenshot of naloxone algorithm treatment recommendations for patient age 19 years 
with bolus therapy. 
 
F) Screenshot of naloxone algorithm treatment recommendation for a 19-year-old patient 
with IVCI therapy. 
Figure 4.21 Screenshot of naloxone algorithm treatment recommendations. 
  
89 
4.3.7 Potassium Iodide 
Radioactive iodine (I-131) is a by-product of nuclear fission.  Though I-131 does have 
medical applications such as treatment of hyperthyroidism, thyroid cancer, and exposure 
from nuclear fallout or a “dirty-bomb” which is often very harmful to humans and can 
lead to very serious health issues.  All dose recommendations are from the Radiation 
Countermeasures for Treatment of Internal Contamination document [68].  When 
recommending doses for a patient exposed to I-131, the AA considers age and pregnancy 
status of the patient.  Neonates (age  0.0833 years or 1 month) with a thyroid exposure 
of 5cGy or higher should receive 16.5mg of KI PO (orally) daily (Figure 4.22 A).  
Toddlers (0.0833 < age 3years) with a thyroid exposure of 5cGy or higher should 
receive 32.5mg KI PO daily (Figure 4.22 B).  Any pregnant patient with a thyroid 
exposure of 5cGy or higher should receive 130mg of KI PO Daily (Figure 4.22 C).  Non-
pregnant children (3< age 12years) with a thyroid exposure of 5cGy or higher should 
receive 65mg of KI daily (Figure 4.22 D).  Non-pregnant adolescents (12< age 18years) 
with weight <68 kg with a thyroid exposure of 5cGy or higher should receive 65mg of KI 
PO daily as well.  Non-pregnant adolescents (12< age 18years) with weight 68 kg with 
a thyroid exposure of 5cGy or higher should receive 130mg of KI PO daily.  Non-
pregnant adults (18< age 40 years) with a thyroid exposure of 10cGy or higher should 
receive 130mg of KI PO daily.  Adults > 40 years with a thyroid exposure of 500cGy and 
higher should receive 130mg of KI PO daily.  It should be noted that KI therapy for 
known or suspected I-131 exposure is common and the exposure thresholds are loose 
guidelines.  In the case of I-131 exposure it is better to be cautiously prophylactic.  Note 
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that some patients are sensitive to iodine in high concentration, thus this must be taken 
into consideration when treating a patient hypersensitive to KI. A warning message as 
shown in Figure 4.21 I is displayed while running KI antidote algorithm. 
 
 
Screenshot of KI antidote algorithm hypersensitivity warnings. 
 
A) Screenshot of KI antidote algorithm treatment recommendation for neonate (age  
0.0833). 
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B) Screenshot of KI antidote algorithm treatment recommendation for toddler (0.0833 < 
age 3years). 
 
C) Screenshot of KI antidote algorithm treatment recommendation for any pregnant 
patient. 
 
 
D) Screenshot of KI antidote algorithm treatment recommendation for child (3< age 
12years) and not pregnant. 
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E) Screenshot of KI antidote algorithm treatment recommendation for adolescent (12< 
age 18years) weight <68 kg and not pregnant. 
 
F) Screenshot of KI antidote algorithm treatment recommendation for adolescent (12< 
age 18years) weight 68 kg and not pregnant. 
 
G) Screenshot of KI antidote treatment recommendation for adult (18< age 40years) and 
not pregnant. 
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H) Screenshot of KI antidote algorithm treatment recommendation for adult > 40years 
and not pregnant 
Figure 4.22 Screenshots of KI antidote algorithm treatment recommendations. 
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5 CONCLUSION AND DISCUSSION 
In this chapter we first summarize the significance and contribution of the project, 
followed by a brief description of peer response, project and plans for future work, and 
future paper submissions.  Last, we discuss some of the issues surrounding AA that came 
to light during the course of this work. 
 
5.1 Summary of contributions 
We implemented 27 algorithms for the treatment of common toxin exposure in North 
America in both the Java AA and the Web AA.  The Java AA is a robust, stable and 
easily maintainable system available offline as a standalone expert system.  It is 
compatible with all leading operating systems e.g. MS Windows, Mac OS X, and Linux.  
It contains 31 classes, 200 methods, and 2831 lines of code.  The average cyclomatic 
complexity is low (3.337) as well as the average nested block depth (1.45).  The Java AA 
standalone system can be downloaded at http://www.met-
hilab.org/files/antidote/antidote_application.jar.   
The Web AA has the same cyclomatic complexity and average nested block depth as the 
Java AA.  The Web AA contains 2443 lines of code, 34 classes and 200 methods.  The 
Web AA is publically available at http://projects.met-hilab.org/antidote/. 
The AA currently covers the 29 antidotes recommended by Dart et al., 31 specific toxins 
and 19 toxin classes.  These antidotes are the essential antidotes that an expert panel of 
leading clinical toxicologists recommended to be stocked in North American hospitals.  
These specific toxins and toxin classes represent hundreds toxic entities.  Many of the 
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antidotes listed have other clinically approved and unapproved indications.  Atropine for 
instance is essential in advanced cardiac life support (ACLS) [65, 73, 74].  Sodium 
Bicarbonate is used extensively for many other acute indications such as cardiac arrest, 
shock, severe dehydration, primary lactic acidosis, and severe diabetic acidosis to 
mention a few [75].   
The AA provides patient-specific treatment recommendations and dose calculations for 
all age groups ranging from newborns to elderly adults.  All current electronic drug 
database systems provide incomplete information regarding the antidotes described in the 
project.  In section 2.4 we reviewed 14 electronic toxicology databases and three quick 
reference antidote charts. In the area of toxicology, patient specific recommendations and 
calculations were largely non-existent.  Some of the systems have links to calculators.  
While this is a step in the right direction, the calculations are not patient specific, which 
may result in unclear and confusing treatment recommendations.   
Both Java AA and Web AA provide the phone number to Poison Control and a link to the 
FAER.  There is no federal law regarding the reporting of poisoning to Poison Control or 
the FAER.  Some states, however, have adopted mandatory reporting of poisoning to 
Poison Control [10].  Also, the Joint Commission, an independent organization 
authorized by the Centers for Medicare and Medicaid Services in the accreditation and 
certification of health organizations, requires the reporting of adverse events as a part of 
its core accountability measures [76].  The Joint Commission also requires that the toll-
free Poison Control phone number be readily available throughout the hospital.  Making 
these resources readily available assists healthcare organizations in complying with state 
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law and in their accreditation effort.  Of all of the electronic systems and quick reference 
charts in print reviewed in this project, only Medline Plus, a service of the U.S. National 
Library of Medicine, has both the Poison Control number and the link to the FAER.  
Both AA systems are thoroughly tested and all algorithms are fully referenced. Every 
effort was made to ensure that references are up-to-date and that the system is 
operationally robust.  Identifying references was at times difficult especially in the 
treatment of neonate to pediatric (generally 0 to 12 years).  Two primary literature 
articles provide useful information and leads on pediatric and neonatal dosing [65, 66].  
For background understanding of the mechanisms of toxicity and the basis for most 
antidote treatment, Goldfrank's Manual of Toxicologic Emergencies has proved to be a 
valuable source [55].  Many of the primary literature articles used in the project cited 
Goldfrank’s for background information.  Without these sources, this project would have 
been much more difficult. 
 
5.1.1 Maintaining the Antidote Application 
Currently, we are laying the groundwork for continued maintenance of the AA.  The 
author will maintain the clinical aspects of the project post-graduation as well as the Java 
AA.  Members of BU MET Health Informatics Lab will maintain the Web AA and the 
Mobile AA that is currently under development.  Clinical reviews are to be completed on 
a quarterly basis by first reviewing the Daily Med (a service of the U.S. National Library 
of Medicine) database of drug monographs for FDA approved updates.  Then the primary 
literature used for the three unapproved use antidotes (ethanol, glucagon, and octreotide) 
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and the one ambiguous use antidote, calcium chloride/calcium gluconate, will be 
reviewed.  Last, the primary literature for neonates and pediatric patients will be 
reviewed.  Updates will then be distributed to team members for application updates.  
 
5.1.2 Changing the JAVA AA layout 
Further work on the Java AA layout has been proposed and is underway.  To have a 
unified appearance for the user interfaces of Java AA and Web AA, team members have 
approved adding tabs to the Java AA user interface using the Java Swing component 
JTabbedPane.  The proposed layout has a Home, Antidote, and Toxin tabbed pane as 
illustrated in Figure 5.1.  The Home tab will host instructions for using the system, 
Poison Control phone number and the FAER link.  At the moment there is debate on 
whether to keep the age, weight, and height inputs on the home page.  The input fields 
will appear and function on the Antidote and Toxin pages.  The output area in each of the 
pages will utilize the Java Swing component JEditorPane, which can receive HTML as a 
return type.  This enables developers to utilize the various fonts, colors, images and user 
interface features of HTML.  The current return type for the JTextArea output portion is 
limited to single font text.  Utilizing these new features would make the interface more 
conducive to expanding the level of patient specific output to include clinical monitoring 
parameters and supportive care therapy checklists for clinical users.  Drug warnings may 
be made clearer by increasing the font of the text and/or changing the color of the text.  
Some of the user input windows may be embedded in the JEditorPane.  Look-alike and 
sound-alike questions for user input often introduce human errors when presented 
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together to users.  When we need users to answer a set of questions containing multiple 
very similar sounding questions, a separate window may be used to present the questions 
one by one to reduce the likelihood of introducing human errors.  Images may also be 
used in the JEditorPane to visualize administration instructions in graphic detail.   
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5.1.3 Validation of the AA 
To investigate how the treatment plans recommended by the AA correspond to those 
actually used in clinical setting, we plan to compare the treatment recommendations in 
AA with real-life treatment data in patient information databases, such as I2B2 
(Informatics for Integrating Biology and the Bedside) (https://www.i2b2.org/), a database 
and informatics framework funded by the National Center for Biomedical Computing and 
based at Partners Health Care System.  The biomedical framework allows clinical 
researchers to use the existing clinical data for discovery research.  We plan to 
systematically compare the AA treatment recommendations with the patient treatment 
data hosted in I2B, study the discrepancies between them, and make improvements to the 
AA based on the acquired knowledge. 
5.1.4 The publication plan 
Plans for submitting this work for publication has been discussed in three areas of 
medicine; toxicology, pharmacotherapy, and biomedical informatics.  In the toxicology 
adaptation the paper will focus on the implementation of the toxicological algorithms that 
calculate drug doses and make individualized therapy recommendations for acute care 
situations.  For the pharmacotherapy aspect, the paper uses the AA as a new model for 
presenting drug information.  Currently, drug information databases and CDSSs do not 
pare information for patient specific use.  The AA is the first drug information CDSS to 
uncover patient specific recommendations by pruning away extraneous indications, 
routes of administrations, and dose ranges.  Further, the AA incorporates patient specific 
dose calculations into the treatment recommendations.  All of the drug information 
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systems reviewed in section 2.4 lack this very important feature.  The AA is the first 
publically available system to present patient specific drug information and dose 
calculations in toxicology.  As it stands broadly in the field of drug information decision 
support, the AA is the first to remove all extraneous information (irrelevant indications, 
mechanisms of action, toxicity, routes of administration, etc.) and provide specific drug 
calculations and treatment recommendations for a single pertinent indication.  Pharmacist 
peer reviewers of the AA have responded positively to the idea of presenting drug 
information for a single indication that contains patient specific recommendations and 
drug calculations. The health informatics aspect of the paper will focus on the 
implementation of an expert drug information system.   
5.1.5 Transformation from educational to point of care system 
We plan to engage practicing toxicologists to review the AA. With their validation and 
endorsement, it has the potential to be a point of care clinical decision support system in 
addition to being an educational system.  An Android mobile version and an iOS version 
of the AA are presently under development.  The mobile apps represent a significant 
expansion of the AA project, which may bring the project closer to bedside. The Android 
platform is based on Java, which would require fewer changes to the original Java AA for 
adaptation to the Android mobile platform.  NetMarketShare.com shows Android has 
now eclipsed iOS in sales of mobile and tablet operating systems, which means that 
Android is beginning to reach a larger market [77].  In a report published by the IMS 
Institute for Health Informatics the Apple iTunes store listed 43,689 in 2013, the Google 
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Play store listed 33,252 medical and healthcare applications in 2013 [78].  We are at the 
early stage of developing the Android AA app as shown in Figure 5.3.  
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Figures 5.3 Screenshots of the 
mobile version of the AA, A) 
screenshot of the homepage; B) 
and C) screenshots of pages in 
acetylcysteine algorithm. 
 
 
 
 
 
 
 
 
5.1.6 Advanced cardiac life support (ACLS) module for adjunct therapy. 
Other modules have been proposed to expand and accommodate the acute care nature of 
the AA.  An advanced cardiac life support (ACLS) module has been discussed.  An 
ACLS module is the next logical step in expanding the AA, as many life-threatening 
exposures require supportive ACLS therapy in addition to antidote therapy.  To maintain 
our goal of providing drug information for all age groups, a pediatric acute life support 
system (PALS) should be integrated as well.   
Figure 5.2 C) Screenshot of mobile AA in acetylcysteine 
algorithm 
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F&C currently has an ACLS module that calculates patient specific doses [38].  
Unfortunately, it calculates the dose for all ACLS medications and scenarios and presents 
them to the user all at once.  There are six different scenarios and 31 different dose 
recommendations, resulting in a long and confusing report for cardiac life support.  
Several medications are used for more than one of the 6 ACLS algorithms– ventricular 
fibrillation/tachycardia, asystole/pulseless electrical activity, bradycardia, tachycardia, 
acute coronary syndromes, and acute stroke.  Often they are dosed differently for 
different indications.  For instance epinephrine is used in three ACLS scenarios 
(ventricular fibrillation/tachycardia, asystole/pulseless electrical activity and bradycardia) 
and is dosed differently in each one of them. When a large amount of extraneous 
information is presented to the user, it results in information overload, which is not 
helpful in a medical crisis.  The proposed ACLS and PALS modules would follow the 
same format as the AA. Specific medication(s) may be chosen for a specific indication.  
For instance if a user were to choose the bradycardia algorithm, the user would be 
presented with treatment and dose recommendations for atropine, epinephrine, and 
dopamine.   
5.2 Discussion 
One issue encountered in the course of the project was verification of primary literature 
sources used in subscription-based drug information databases.  Publishing 
conglomerates own three of these databases.  Facts & Comparisons and Lexicomp are 
subsidiaries of Wolters Kluwer Health, which also owns Lippincott, Williams & Wilkins 
and Ovid [79].  Lippincott Williams & Wilkins and Ovid are large electronic medical 
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journal databases.  Facts & Comparisons and Lexicomp almost exclusively use primary 
literature from the Lippincott Williams & Wilkins and Ovid databases for unapproved 
uses and pediatric dosing.  This may seem logical.  However, for the average consumer 
that would like to read and verify the primary literature source, a very expensive fee must 
be paid.  Clinical Pharmacology is a subsidiary of Elsevier, which has a large electronic 
medical journal and book database.  Similarly many of their primary literature references 
for unapproved uses and pediatric dosing come from their own database.  Though many 
are available to public through PubMed Central, some are available only if a hefty fee is 
paid.  All three of the drug information databases have a yearly licensing fee on the order 
of thousands of dollars for private clinical users.  To verify the primary source by paying 
a premium for each source reviewed is cost prohibitive.  Fortunately, the Boston 
University Library and several project collaborators were able to provide all of the 
necessary literature sources for the AA.  Still the notion that Wolters Kluwer and Elsevier 
can charge an excessive fee for an article they own and cite with one of their products a 
user has already paid a premium for appears to violate the rule of reason for vertical 
relations antitrust laws.   
The preface of this thesis reveals the conditions in which the idea for this type of decision 
support system was conceived.  I would like to revisit that issue and illustrate the 
meaningful educational use of the AA.  The “July effect” is named for a documented 
phenomenon that occurs each year in teaching hospitals [11].  In July, medical students 
become interns and interns become residents.  Both groups are given a large amount of 
new responsibilities including medication transcription and ordering.  Their inexperience 
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with medications and medication ordering is reflected in a concomitant increase (10%) in 
the number of medication error related deaths. 
Interns and residents are expected to take as little time as possible on writing admission 
and transfer orders.  Their unfamiliarity with the hospital formulary (list of medications 
the hospital stocks) creates a very steep learning curve and an environment ripe for error.  
The new physicians must educate themselves on the proper dosage and administration of 
medications in which they are unversed.  In the press for rapid patient throughput, they 
often do not adequately research the medications they are ordering because of the 
complexity of the drug information presentation.  After several experiences with order 
error, young physicians begin to rely on other staff members to reduce the drug 
information to an appropriate amount for a specific indication and patient type.  Often 
clinical hospital pharmacists are contacted in this situation.  Once inexperienced 
physicians begin to utilize hospital resources in this manner, fewer errors are made.  The 
Antidote Application similarly pares drug information rapidly and generates patient and 
indication specific dosing and treatment recommendations.  This is a unique educational 
tool for the new intern and resident in treatment of drug overdose.  Not only can it reduce 
the time spent to create orders, the AA’s clear presentation format enables rapid 
education of users.  As a result, the AA potentially prevents medication error related 
injury and death that frequently occurs with new physicians.   
To the best of our knowledge, the AA is the first educational and decision support system 
in toxicology that provides patient-specific treatment recommendations and drug dose 
calculations.  
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6 APPENDIX A:   
6.1.1 Atropine 
Atropine is used as an antidote for organic phosphorus and carbamate insecticides (FDA 
approved use).  Organic phosphorous and carbamate insecticides cause toxicity by 
inhibiting the activity of the enzyme acetylcholinesterase.  This causes a build up of 
acetylcholine at muscarinic receptors.  Atropine acts as an antagonist to inhibit 
acetylcholine at muscarinic receptors.  Atropine reverses the acute adverse effects of 
insecticides – defecation, urination, miosis, bronchospasm or bronchorrhea, emesis, 
lacrimation, and salivation [55, 73].   
The key factors in developing the atropine treatment algorithm were age, weight and drug 
delivery device used.  Infants under 7kg can receive an overdose with the use of a preset 
atropine auto-injection device.  Children less that 1 year old must be dosed individually 
by calculating the exact amount (0.01-0.03mg/kg IV or IM) and withdrawing it from a 
vial of atropine for injection.  Children aged 1 to 21 years of age should receive 
0.05mg/kg per dose IV or IM up to the adult dose of 3mg.   Atropine auto-injectors are to 
be used in patients weighing 7kg or more.  In 7kg up to 18kg patients the 0.5mg atropine 
auto-injector (IM) should be used.  In 18kg up to 41kg patients the 1mg atropine auto-
injector (IM) should be used.  In patients 41kg and greater the 2mg atropine auto-injector 
(IM) should be used.  Figure 3.11 describes the dosing and usage algorithm of atropine 
auto-injectors and atropine vials for injection [55, 73] 
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6.1.2 Calcium Chloride and Calcium Gluconate 
Calcium chloride (CaCl) and calcium gluconate are two calcium salts used in the 
treatment of calcium channel blocker (CCB) and fluoride overdose.  FDA labeled use of 
CaCl for injection states, “10% Calcium Chloride Injection, USP is indicated for the 
treatment of hypocalcaemia in those conditions requiring a prompt increase in plasma 
calcium levels. [80]” FDA labeled use of calcium gluconate states an extensive list of 
specific conditions that can lead to the use of calcium, but never explicitly states that it 
can be used in CCB and fluoride overdose.  Tertiary literature sources disagree on 
whether or not these two agents are approved for these indications.  For instance clinical 
pharmacology states that these are approved uses [81, 82].  Lexicomp states that they are 
off-label uses [83, 84]  Primary literature sources yielded the most information about 
calcium salts dosing  [65, 66, 85-88]. 
CCBs block the slow calcium channel conductivity in myocardial and smooth muscle.  
This causes decreased cardiac muscle contractility, reduced heart rate (bradycardia) and 
dilation of peripheral (smooth muscle regulated) vasculature, which results in lowered 
blood pressure (hypotension). In high dose this leads to potentially fatal hypotension [55].   
Hydrofluoric acid (HFl) is easily absorbed through the skin (transdermally), the eyes, and 
via inhalation as it has a high permeability coefficient.  The fluoride ion readily binds 
intracellular calcium and magnesium, which leads to rapid dysfunction and cell death.  
As little as 1mg/kg of fluoride is lethal in humans.  HFl is commonly found in household 
cleaning products. 
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In CCB poisoning, administration of calcium salts improves cardiac muscle contractility.  
Heart rate and contractility are improved only in extremely high doses.  In fluoride 
poisoning calcium binds the fluoride and replenishes calcium at the site of exposure. 
CaCl contains 3 times the elemental calcium in the same amount of calcium gluconate.  
Though CaCl is the preferred agent in toxicity, it must be given through a central line as 
it is highly acidifying.  Under certain circumstances calcium gluconate is the preferred 
agent as it is less likely to be as caustic to the surrounding tissue. 
For dosing calcium chloride in adults, administer 20mg/kg slow IVP over 10-15 minutes 
via central line.  Then begin IV infusion of (20 to 50mg/kg) per hour and titrate to desired 
effect [88]. 
For dosing calcium chloride in children administer 20mg/kg slow IVP via central line 
over 15 minutes.  Dose may be repeated in 10 minutes if necessary.  IV continuous 
infusion at 20 to 50 mg/kg per hour may be considered if bolus therapy is beneficial [65]. 
For dosing calcium gluconate in adults administer 60mg/kg of calcium gluconate slow 
IVP over 10-15 minutes.  Then begin IV infusion of 60-150mg/kg per hour and titrate to 
desired effect. 
For dosing calcium gluconate in children administer 100mg/kg (maximum 3grams) slow 
IVP via central line over 15 minutes. Dose may be repeated in 10 minutes if necessary 
[66].
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6.1.3 Ca-DTPA/Zn-DTPA 
Ca-DTPA and Zn-DTPA (DTPA) are used for the decontamination of known or 
suspected ingestion of americium, curium, or plutonium (FDA approved) [89].  
Americium, curium, and plutonium are radioactive heavy metals.  Ionizing radiation from 
them can create free radicals in the cell and subsequent damage. They can also cause 
damage to essential molecules in the cell such as DNA.  DTPA is a chelator that binds the 
radioactive heavy metals and increases their rate of excretion [55].  The most significant 
factors in dosing DTPA are age and weight.  Children younger than 12 years old should 
receive 14mg/kg (up to 1000mg) via slow IVP or oral inhalation as soon as possible after 
initial exposure.  Adults should receive 1 gram of DTPA as soon as possible after initial 
exposure.  There is limited effectiveness after 24 hours have lapsed since exposure.  Zn-
DTPA can be used if Ca-DTPA is not available.  Ca-DTPA is the preferred agent [89]. 
 
Figure 6.3 Ca-DTPA (plutonium, americium, and curium toxicity) algorithm. 
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6.1.4 Calcium disodium EDTA (EDTA) & Dimercaprol 
EDTA and Dimercaprol are used in tandem in the treatment of lead toxicity 
encephalopathy and (FDA approved) [90, 91].  There are three main pathophysiological 
pathways in which lead affects the human body.  First, it has a high affinity for many 
receptors and binding sites.  Second, it mimics calcium in the body.  Third, it exhibits 
mutagenic effects on mammals.  As a result lead toxicity can cause neurotoxicity.  Lead 
can also have harmful effects on the hematologic, renal, cardiovascular, reproductive, 
endocrine, skeletal, and gastrointestinal system [55].  EDTA binds lead and increases the 
rate of excretion.  The most significant factors for developing the algorithm were the 
presence of encephalopathy, blood plasma concentrations of lead (PbL), age and weight.  
In children with encephalopathy administer dimercaprol 4mg/kg IM Q4h and dose EDTA    
1500mg/m^2/day (max 1000mg/day) IVCI 4 hours after first dimercaprol dose up to 5 
days or till acceptable Pb value.  In children 12 years and younger without 
encephalopathy and a PbL of 70mcg/dl or higher administer dimercaprol 4mg/kg IM Q4h 
and dose EDTA1000mg/m^2/day (max 1000mg/day) IVCI 4 hours after first dimercaprol 
dose up to 5 days or till acceptable Pb value.  In children 21 years and younger with no 
encephalopathy and a PbL greater than 45mcg/dl and less than 70mcg/dl, administer 
EDTA 1000mg/m^2/day (max 1000mg/day) per day IVCI for up to 5 days or till normal 
Pb value achieved[90, 91].   
In patients greater than 12 years old with encephalopathy administer dimercaprol 4mg/kg 
IM Q4h and dose EDTA 1500mg/m^2/day (max 3000mg/day) IVCI 4 hours after first 
dimercaprol dose up to 5 days or till acceptable Pb value achieved.  In patients greater 
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than 12 years old without encephalopathy and a PbL of 70mcg/dl or higher administer 
dimercaprol 4mg/kg IM Q4h and dose EDTA 1000mg/m^2/day (max 3000mg/day) IVCI 
4 hours after first dimercaprol dose up to 5 days or till acceptable Pb value achieved.  In 
adults older than 21 years old with no encephalopathy and a PbL greater than 45mcg/dl 
and less than 70mcg/dl treatment is at the discretion of the physician [90, 91].  
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6.1.5 Coral Snake Antivenin 
Antivenin (Micrurus fulvius) North American Coral Snake Antivenin CSAV is used in 
the treatment of envenomation by all North American coral snakes except for the 
Sonoran or Arizona Coral snake (FDA approved) [92].  Coral snakes belong to the 
Elapidae family.  There venom consists of several unknown neurotoxins, which cause 
systemic neurotoxicity instead of local tissue damage.  CSAV antibodies neutralize the 
venom components of the coral snake and prevent systemic toxicity.  Significant factors 
in creating the coral snake antivenin algorithm include age and sensitivity to horse serum 
products.  A skin sensitivity test should be performed first.  If a patient is sensitive to the 
CSAV, a desensitization protocol should be administered before proceeding to the full 
rate of administration.  Children and adults should receive 3 to 5 vials of CSAV. The 
preferred method is started with a 250 to 500ml sodium chloride 0.9% infusion.  The 
CSAV can be added to the IV infusion or it can be pushed in the same IV infusion line.  
In children the volume of the IV infusion may need to be decreased.  IM dosing is 
available but not recommended.  The total volume administered is 30 to 50 ml, which 
would translate to 15 to 25 intramuscular injection sites (2ml max per site) [92]. 
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Figure 6.5 Coral snake envenomation algorithm.
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Figure 6.6 Coral snake variables.
  
120 
6.1.6 Crotalidae Antivenin (Ovine Derivation) – North American Pit Viper 
Crotalidae Antivenin (CroAV) is used in the management of patients with North 
American crotalid envenomation (FDA approved) [93].  Examples of North American 
crotalids CroAV is effective against include rattlesnakes, copperheads, and 
cottonmouth/water moccasins.  Crotalid venom can contain many unidentified proteolytic 
enzymes, anticoagulants, neurotoxins, and cardiotoxins.  It can cause localized tissue 
damage and present systemic effects via circulation [55].  CroAV is a venom-specific 
fragment of IgG (Fab) that binds and neutralizes crotalid venom.  This helps speed the 
removal of venom from the body [93].  Important considerations when developing the 
CroAV algorithm were ovine (sheep) derived product sensitivity and age.  The dose for 
patient’s 12 years of age and younger is expected to be the same as adults and 
adolescents.  The previous statement may appear to be a redundancy.  However, the drug 
monograph uses similar language.  Adults and adolescents should receive - 4 to 6 vials of 
CroAV initially.  Monitor for one hour and repeat 4-6 vials if desired effect is not 
achieved.  Then 2 vials of CroAV every 6 to 18 hours until symptoms abate.   
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6.1.7 Hydroxocobalamin, Amyl Nitrite, Sodium Nitrite, Sodium Thiosulfate 
Hydroxocobalamin is used in the treatment of known or suspected cyanide poisoning 
(FDA Approved) [94].  Cyanide inhibits many enzymes.  Among those, one of the most 
important being cytochrome oxidase which is used in oxidative phosphorylation (aerobic 
energy production).  This induces cell hypoxia.   Cyanide is also a potent neurotoxin that 
greatly affects areas of the brain with high metabolic activity [55].  Hydroxocobalamin’s 
mechanism of action is to bind cyanide ions in a form that is rapidly excreted [94].  The 
Cyanide Antidote Kit consists of amyl nitrite, sodium nitrite, and sodium thiosulfate. 
Sodium thiosulfate combines with cyanide to form thiocyanate, which is less toxic and 
readily excreted. The nitrites in the kit combine with hemoglobin to form 
methemoglobin, which reacts with cyanide to form cyanmethemoglobin a less toxic 
cyanide derivative [95].  Significant considerations when creating the cyanide treatment 
algorithm included age, weight, and product availability.   
Our recommendation for treating cyanide poisoning in adults is hydroxocobalamin 5 g (in 
children 70mg/kg up to 5000mg) IV infused over 15 minutes. A second dose infused over 
15 minutes to 2 hours for a total to 10g (in children 140mg/kg up to 10000mg), may be 
administered based on clinical response and severity of cyanide poisoning. Cyanokit: In 
adults and children break vial and inhale the contents of 1 ampule (0.18—0.3 mL) for 
15—30 seconds.  Repeat 1 ampule dose every minute until sodium nitrite IV infusion is 
available.  The sodium nitrite intravenous dosage in adults is 300 mg IV at a rate of 2.5 to 
5 ml/minute, in children 0.15-0.33 ml/kg up to 300mg. Do not to exceed 10 ml of a 3% 
sodium nitrite solution. Whether used alone or in combination with other cyanide 
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antidotes, the usual dosage of sodium thiosulfate in adults is 12.5g given IV over a period 
of approximately 10 minutes.  In children the usual dosage of sodium thiosulfate is 7 
grams/m^2 of body surface area (BSA). If symptoms of cyanide toxicity recur, one half 
of each dose of sodium nitrite and sodium thiosulfate may be repeated after 30 minutes. 
Elderly patients may be more sensitive to the hypotensive effects of nitrites [95]
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6.1.8 Digoxin Immune FAB 
Digoxin Immune FAB (DigiFAB) is used in the treatment of life-threatening or 
potentially life-threatening digoxin overdose (FDA approved) [96].  Digoxin binds the 
alpha-subunit of the sodium/potassium ATPase pump in myocardial cells.  Inhibition of 
the pump leads to increased intracellular sodium and consequently increased intracellular 
calcium.  The increased intracellular calcium leads to increased contractility of the 
myocardium.  In digoxin overdose, this massive shift in stores of intracellular sodium 
leads to dangerous levels of potassium in the blood.  This causes life-threatening 
tachydysrhythmias (fast irregular heartbeats) in the heart.  Chronic toxicity occurs in 
patients that have been receiving digoxin as therapy when some event triggers toxic 
digoxin levels.  Acute toxicity occurs in patients that are digoxin naïve and ingest a life-
threatening dose [55].  When administered DigiFAB binds digoxin as it has a higher 
affinity than the sodium/potassium ATPase pump.  This decreases the free digoxin in the 
blood and shifts potassium levels in the blood from cardiotoxic toward normal.  Careful 
monitoring of potassium is necessary as the levels may drop too low [96].  When 
developing the DigiFAB algorithm the most important factors to consider were the type 
of toxicity (acute or chronic), serum digoxin levels in chronic toxicity, amount taken in 
acute toxicity, and weight.  In chronic toxicity if the digoxin levels are unknown, patients 
weighing ≥ 20kg should receive 6 vials of DigiFAB IV – less than 20kg the patient 
should receive 1 vial of DigiFAB.  If the serum digoxin levels are known in chronic 
toxicity, the dose should be based on serum levels  -  
dose (in vials) = (serum_digoxin ng/ml)*(weightkg)/100.   
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In acute toxicity, if the amount of digoxin taken is unknown patients should receive 10 
vials of DigiFAB IV followed by 10 vials more if necessary.  Patients under 20kg should 
be monitored for volume overload.  If the dose is known of the acutely toxic, the dose 
calculated is based on the formula - 
dose (in vials) =  (digoxin_mg)/ (0.5 mg/vial). 
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6.1.9 Dimercaprol (heavy metals other than lead) 
Dimercaprol is used in the treatment of the heavy metals arsenic, gold and mercury 
poisoning (FDA approved) [91].  Toxicity caused by them results in widespread 
enzymatic dysfunction and can lead to body system failures.  These heavy metals bind 
readily to the ubiquitous sulfhydryl groups found throughout the body.  The dimercaprol 
sulflhydryl group binds heavy metals and creates a chelate that is readily excreted in 
urine.  Dosing of dimercaprol in mild arsenic or gold toxicity includes dimercaprol 2.5 
mg/kg and 3mg/kg in severe toxicity deep IM four times daily for two days, two times on 
the third day, and once daily thereafter for ten days.  For mercury poisoning, dimercaprol 
dosing includes 5mg/kg initially, then 2.5mg/kg deep IM once or twice daily for 10 days. 
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6.1.10 Ethanol 
Ethanol is used as a second line agent for the treatment of methanol and ethylene glycol 
poisoning (not approved) [47, 55, 97].  Unimpeded, methanol and ethylene glycol both 
are rapidly metabolized in the body by alcohol dehydrogenase, then aldehyde 
dehydrogenase, which leads can lead to the buildup of toxic metabolites.  Alcohol 
dehydrogenase has a greater affinity for ethanol and less toxic metabolites.  Ethanol 
effectively blocks the alcohol dehydrogenase pathway when administered during 
methanol or ethylene glycol poisoning.  This forces methanol and ethylene glycol to be 
eliminated by other means. The most significant factors in creating the ethanol algorithm 
were weight and whether the patient is a chronic alcoholic beverage drinker.  For 
methanol and ethylene glycol poisoning, initial dosing of ethanol in the chronic drinker 
and non-drinker is 8ml/kg 10% ethanol in D5W IV infusion.  This is followed by 2ml/kg 
IVCI in chronic drinkers and 0.8ml/kg in non-drinkers.  Therapy should continue in 
patients until methanol and ethylene glycol levels are below 20mg/dl [47, 55].  
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Figure 6.11 Ethanol algorithm for methanol and ethylene glycol toxicity. 
 
6.1.11 Flumazenil 
Flumazenil is used in the treatment of benzodiazepine overdose (FDA approved) [98].  
Benzodiazepines stimulate the benzodiazepine receptor that modulates the effect of the 
gamma-amino-butyric acid (GABA) receptor.  Stimulating this receptor increases the 
frequency of the opening of the chloride channel.  The systemic effects in benzodiazepine 
toxicity lead to respiratory depression and possible cardiopulmonary de-compensation.  
Death caused solely by benzodiazepine overdose is rare.  Benzodiazepine deaths are 
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usually the result of being mixed with another agent such as alcohol or a sedative-
hypnotic.  Flumazenil competes with benzodiazepines at the benzodiazepine receptor.  
Flumazenil binds to the receptor but has none of the effects on the GABA receptor 
chloride channels.  This effectively blocks the effects of the benzodiazepines until they 
can be eliminated from the body [55].  Special considerations when developing the 
antidote algorithm include age and weight.  
In flumazenil dosing of children 18 years old and younger the recommended initial dose 
is 10 mcg/kg (up to 200 mcg) administered intravenously over 15 seconds. If the desired 
level of consciousness is not obtained after waiting an additional 45 seconds, further 
injections of 5 to 10 mcg/kg (up to 200 mcg) can be administered and repeated at 50-
second intervals where necessary (up to a maximum of 4 additional times) to a maximum 
total dose of 50 mcg/kg or 1 mg, whichever is lower. 
For patients greater than 18 years of age, the recommended initial dose of flumazenil 
injection is 0.2 mg (2 mL) administered intravenously over 30 seconds. If the desired 
level of consciousness is not obtained after waiting 30 seconds, a further dose of 0.3 mg 
(3 mL) can be administered over another 30 seconds. Further doses of 0.5 mg (5 mL) can 
be administered over 30 seconds at 1-minute intervals up to a cumulative dose of 3 mg 
[66, 98]. 
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6.1.12 Fomepizole 
Fomepizole is the preferred agent in the treatment of methanol and ethylene glycol 
poisoning (FDA approved) [99].  Unimpeded, methanol and ethylene glycol are 
metabolized by alcohol dehydrogenase, which catalyzes the formation of toxic 
metabolites in the body.  If untreated these toxic substances lead to metabolic acidosis 
and subsequent system failures (mainly renal) and death.  Fomepizole has a greater 
affinity for alcohol dehydrogenase than methanol, ethylene glycol and most other 
alcohols.  Upon administration, fomepizole blocks the toxic pathway and forces methanol 
and ethylene glycol to be excreted in a different and less toxic manner [99].  
The most important factors considered when creating the fomepizole algorithm were 
weight and serum concentrations of the toxin.  Dosing of patients with an unknown 
serum concentration or a serum concentration greater than 20mg/dl of methanol or 
ethylene glycol should receive a loading dose of 15 mg/kg, followed by doses of 10 
mg/kg every 12 hours for 4 doses, then 15 mg/kg every 12 hours (fomepizole hinders 
metabolism) thereafter until ethylene glycol or methanol concentrations are undetectable 
or have been reduced below 20 mg/dL, and the patient is asymptomatic with normal pH.  
Patients with serum concentrations above 50mg/dl should receive dialysis in addition to 
the dosing protocol described above.  Patients with serum concentrations of 20mg/dl or 
less should have serum concentrations and symptoms monitored with no fomepizole 
therapy [99].  
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6.1.13 Glucagon 
Glucagon is used for the treatment of beta-blocker and calcium channel blocker overdose 
(unapproved) [47, 55, 66, 100].  Beta-blocker and calcium channel blocker overdose both 
cause hypotension, bradycardia, and decreased myocardial contractility [55].  Glucagon 
is a hormone secreted by pancreatic cells.  It increases myocardial contractility and heart 
rate.  It is the drug of choice in beta-blocker poisoning and can also be used in calcium 
channel blocker poisoning in the absence of other superior agents [55].  The significant 
factors that determined the development of the glucagon algorithm were age and weight. 
Dosing of glucagon in patients 12 years old and younger includes a 30 to 150mcg/kg 
bolus followed by 10 to 70mcg/kg/hour IVCI.  Dosing of adolescents greater than 12 and 
up to and including 18 years of age should receive a 5 to 10 mg bolus of glucagon 
followed by 1 to 5mg/hour IVCI.  Patients aged greater than 18 should receive a 3 to 10 
mg IV bolus of glucagon followed by 1 to 5mg/hr IVCI.  
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6.1.14 Methylene Blue 
Methylene blue MB is used in the treatment of drug-induced methemoglobinemia (FDA 
approved) [55, 101].  In drug induced methemoglobinemia, the hemoglobin is able to 
carry oxygen but unable to release it to body tissues.  Upon administration MB is rapidly 
converted to leukomethylene blue by nicotinamide adenine dinucleotide phosphate 
(NADPH).  Leukomethylene blue readily reduces methemoglobin to hemoglobin and 
restores normal transport of oxygen to tissues.  MB is not effective in patients with a 
genetic G6PD deficiency.  G6PD is essential for the generation of NADPH.  MB is 
contraindicated in patients with nitrate-induced methemoglobinemia due to cyanide 
treatment because MB can liberate the cyanide bound by cyanmethemoglobin [55, 101].  
In creating the MB algorithm the most significant factors included whether 
methemoglobinemia was nitrate induced secondary to cyanide treatment, age and weight. 
The MB dose for infants aged 0 up to 1 month with methemolobinemia is 0.3-1 mg/kg 
slow IVP over 3-5 min  - flush line for comfort [102].  The MB dose for patients 1 month 
old and higher is 1-2mg/kg slow IVP over 3-5 minutes - flush line for comfort [55, 101]. 
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6.1.15 Octreotide 
Octreotide is used in the treatment known or suspected hypoglycemia secondary to 
sulfonylurea overdose (not FDA approved) [55, 103-105].  Sulfonylureas stimulate the 
beta cells in the pancreas, which release insulin into the bloodstream.  Insulin binds to 
various tissues in the body and causes the uptake of glucose from blood.  In overdose, the 
effects of sulfonylureas are exaggerated and cause hypoglycemia.  This can be life 
threatening especially in children, diabetics, and elderly patients.  Octreotide is a longer-
acting somatostatin analog.  It has many far-reaching effects in the body.  One of the 
effects, suppression of insulin secretion in the pancreas, is useful in the treatment of 
sulfonylurea overdose. [55]. 
The significant factors that affected the development of the octreotide algorithm were, 
age and weight.  Patients that are ≤ 6 years old should receive 1–2 μg/kg up to 50 μg 
octreotide SubQ (preferred) or IV every 6–12 hours as necessary based on serum blood 
glucose levels [103-105].  Patients 6 years and under should be monitored carefully as 
adverse events have been reported in this age group.  Patients that are older than 6 years 
and equal to or less than 18 should receive 1–2 μg/kg up to 50 μg octreotide SubQ 
(preferred) or IV every 6–12 hours as necessary.  Patients older than 18 should receive 
50μg-100μg of octreotide SubQ (preferred) or IV Q6-12hr as necessary[103-105]. 
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6.1.16 Physostigmine 
Physostigmine is used to reverse life-threatening effects caused by overdose of 
anticholinergic agents (FDA approved) [106]. Hallmark anticholinergic effects are dry 
mucosa, dry skin, flushing of face, hyperthermia, urinary retention and tachycardia.  
Physostigmine reverses these effects by binding to and inhibiting cholinesterase.  Effects 
of cholinesterase inhibition can be seen usually within 2 minutes of injection [55].   
Factors affecting the development of the physostigmine algorithm include age and 
weight.  In children (age ≤ 18) the recommended dosage is 0.02 mg/kg of physostigmine 
intramuscularly or by slow intravenous injection, no more than 0.5 mg per minute. If the 
toxic effects persist, and there is no sign of cholinergic effects, the dosage may be 
repeated at 5 to 10 minute intervals until a therapeutic effect is obtained or a maximum of 
2 mg dosage is attained.  In adults (age > 18), the recommended dosage is 0.5-2mg IV, 
IM.  May repeat every 10–30 minutes until desired response [106-108]. 
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6.1.17 Pralidoxime 
Pralidoxime is used as a second-line antidote in the treatment of known or suspected 
organophosphorus and/or carbamate insecticide poisoning (FDA approved) [109].  As 
you may recall from the atropine discussion earlier, organophosphorus and carbamate 
insecticides bind the acetylcholinesterase enzyme and consequently create a buildup of 
acetylcholine at synapses.  This can lead to a severe cholinergic response and even death.  
Pralidoxime displaces these substances and regenerates acetylcholinesterase for normal 
synaptic function.  If administered in time, pralidoxime can also prevent the permanent 
bonding of organophosphorous insecticides to the acetylcholinesterase enzyme [55]. 
Significant factors considered in the development of the pralidoxime algorithm include 
age, weight, presence of pulmonary edema, and route of administration.  The pralidoxime 
dose schedule is as follows:  In patients less than 16 years or ≤ 40 kg, administer 20-50 
mg/kg*pralidoxime IV (max 2000 mg/dose) over 15-30 minutes. May give second dose 
of 20-50 mg/kg after about one hour if muscle weakness persists. Repeat dosing every 
10-12 hours as needed. If IVPB or IVCI is not practical, or if pulmonary edema is 
present, give 20-50 mg/kg dose slow IVP  (over not less than five minutes) as a 50 
mg/mL solution. Additional doses may be given every 10-12 hours if muscle weakness 
persists.  If IV dosing is not feasible in this group, give 15mg/kg IM to anterolateral thigh 
Q15 min PRN (Max 3doses).  If symptoms are severe, give 3 doses in rapid succession.   
For patients 16 years and older or greater than 40 kg, inject an initial dose of 1000 to 
2000 mg of pralidoxime IVPB in 100 mL of NS, over 15-30 min.  If this is not practical 
or if pulmonary edema is present, the dose should be given slow IVP (over five minutes 
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or more), as a 50mg/mL solution in water (e.g., 1000 mg in 20 mL).  A second dose of 
1000 to 2000 mg may be given in about one hour if muscle weakness persists.  
Additional doses may be given every 10-12 hours if muscle weakness persists.  If IV 
dosing is not feasible, give 600mg pralidoxime in 2ml IM Q15min PRN (3doses max).  If 
symptoms are severe give the 3 doses in rapid succession [109]. 
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6.1.18 Prussian Blue  
Prussian blue is used in the treatment of patients with known or suspected internal 
contamination with radioactive cesium and/or radioactive or non-radioactive thallium 
(FDA approved) [110].  Cesium and thallium mimic potassium in the body.  They are 
distributed to areas of the body where high concentrations of potassium are found.  
Radioactive cesium and thallium impart ionizing damage to the surrounding tissues 
where potassium would normally localize.  Non-radioactive thallium poisoning affects 
many systems in the body by disrupting the normal use of potassium.  Prussian blue is 
insoluble and not absorbed by the gastrointestinal tract.  When administered orally its 
mechanism of action is to adsorb cesium and thallium (radioactive or non-radioactive) via 
ion exchange [55, 110].   
The significant factor in developing the Prussian blue algorithm was age.  Dosing in 
children 0-2 years of age has not been established.   However, the U.S. Department of 
Health and Human Services’ Biomedical Advanced Research and Development 
Authority has awarded a contract to Heyltex Corp., Katy, Texas, for advanced 
development of a safe and effective way to administer Prussian Blue to infants ages 
newborn to two years old who may have ingested radioactive material as a result of a 
dirty bomb or nuclear fallout.  In children greater than 2 years up to and including 12 
years, the recommended dose of Prussian blue insoluble is 1 gram orally three times a 
day.  In patients older than 12 years the recommended dose of Prussian blue insoluble is 
3 grams orally three times a day [110]. 
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6.1.19 Pyridoxine (Vitamin B-6) 
Pyridoxine is used as an antidote in the treatment pyridoxine deficiency caused by 
isoniazid (INH)  (FDA approved) [111].  It is also used in the treatment of 
gyromytrin/hydrazine toxicity (unapproved) [55].  Both toxins interfere with the normal 
function of pyridoxine a substrate in over 100 essential functions in the body.  Over time, 
the pyridoxine deficiency can lead to seizure [55].  Pyridoxine administration replenishes 
the depleted stores caused by INH and gyromytrin/hydrazine exposure.   
Important factors in developing the pyridoxine algorithm were the type of exposure (ING 
or gyromytrin/hydrazine), dose of INH, age, and weight. 
For patients exposed to gyromytrin/hydrazines, administer 25mg/kg IV over 15-30min in 
children and adults.  May repeat dose as necessary to control seizures (max 15g/day). 
For patients exposed to INH, with weightkg >71kg or Age>18:  If the dose is known give 
pyridoxine IV in a dose equal to amount of INH ingested (max 5000mg per dose). May 
repeat dose Q5-10 minutes to control seizure. If seizures stop prior to administration of 
total dose, the remainder may be given over 4-6 hours.  If the dose is unknown, give 
5000mg IV at a rate of 500-1000mg/min.  May repeat Q5-10min to control seizures. 
For patients exposed to INH, with weightkg ≤ 71kg or Age≤18:  If the dose is known, 
give pyridoxine IV total dose equal to amount of INH ingested.  Up to 70mg/kg or 
5000mg per dose whichever is less may repeat dose Q5-10 minutes to control seizure.  If 
seizures stop prior to administration of total dose, remainder may be given over 4-6 
hours.  If the dose is unknown give 70mg/kg IV (max 5000mg) at a rate of 
1000mg/minute may repeat dose Q5-10 minutes to control seizure [47, 55, 111]. 
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6.1.20 Sodium Bicarbonate 
Sodium bicarbonate (Na Bicarb) is used in the management of toxicity caused by sodium 
channel blockers (FDA approved) [12, 55, 75].  Medications with sodium channel 
blocking ability alter the normal polarization of the myocardium.  This leads to 
prolongation of the QRS wave and life-threatening cardiotoxicity, ventricular 
dysrhythmias, and hypotension.  Na Bicarb’s mechanism of action is believed to be two-
fold.  First, the elevation in pH caused by Na Bicarb buffer increases the amount of freely 
diffusible non-ionized drug and decreases the ionized drug blocking the sodium channel.  
Second, the sodium effect caused by the sodium component increases the availability of 
sodium ions to pass through open channels [55]. 
The significant factors considered in developing the sodium bicarbonate algorithm 
included duration of QRS wave and weight.  In patients with a QRS wave prolongation 
less than or equal to 0.1 seconds, sodium bicarbonate therapy is not indicated.  In patients 
with a QRS wave prolongation exceeding 0.1 seconds, administer Na Bicarb 1-2mEq/kg 
IVP over 1-2 minutes. Na Bicarb can be repeated as necessary to achieve blood pH of 
7.50-7.55.  The treatment endpoint is narrowing of the QRS wave.  Continuous infusion 
of Na Bicarb is often needed after initial bolus to maintain effect - 150 mEq Na 
Bicarb/liter D5W at twice maintenance.  Monitor QRS, pH, and Na level [12, 55, 75]. 
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